Abstract:
A nucleic acid comprising a base sequence which codes for a CEA family member peptide sequence or nucleic acids having a base sequence hybridizable therewith, replicable recombinant cloning vehicles having an insert comprising such nucleic acid, cells transfected, infected or injected with such cloning vehicles, polypeptides expressed by such cells, synthetic peptides derived from the coding sequence of CEA family member nucleic acids, antibody preparations specific for such polypeptides, immunoassays for detecting CEA family members using such antibody preparations and nucleic acid hybridization methods for detecting CEA family member nucleic acid sequences using a nucleic acid probe comprising the above described nucleic acid.

Description:
CROSS-REFERENCES TO RELATED APPLICATIONS 
     This is a division of application Ser. No. 07/274,107, filed Nov. 2, 1988, now U.S. Pat. No. 5,122,599, which is a continuation-in-part of application Ser. No. 07/207,678, filed Jun. 15, 1988, now abandoned, which is a continuation-in-part application of Ser. No. 07/060,031, filed Jun. 19, 1987, now abandoned, which is a continuation-in-part application of Ser. No. 07/016,683, filed Feb. 19, 1987, now abandoned, which is a continuation-in-part application of Ser. No. 06/896,361, filed Aug. 13, 1986, now abandoned. 
    
    
     BACKGROUND OF THE INVENTION 
     1. Field of the Invention 
     The present invention concerns nucleic acid sequences which code for carcinoembryonic antigen (CEA) antigen family peptide sequences. 
     2. Background Information 
     Carcinoembryonic antigen was first described by Gold and Freedman, J. Exp. Med., 121, 439-462, (1965). CEA is characterized as a glycoprotein of approximately 200,000 molecular weight with 50-60% by weight of carbohydrate. CEA is present during normal human fetal development, but only in very low concentration in the normal adult intestinal tract. It is produced and secreted by a number of different tumors. 
     CEA is a clinically useful tumor marker for the management of colorectal cancer patients. CEA can be measured using sensitive immunoassay methods. When presurgical serum levels of CEA are elevated, a postsurgical drop in serum CEA to the normal range typically indicates successful resection of the tumor. Postsurgical CEA levels that do not return to normal often indicated incomplete resection of the tumor or the presence of additional tumor sites in the patient. After returning to normal levels, subsequent rapid rises in serum CEA levels usually indicate the presence of mestastages. Slower postsurgical rises from the normal level are most often interpreted to indicate the presence of new primary tumors not previously detected. Post surgical management of colon cancer patients is thus facilitated by the measurement of CEA. 
     CEA is a member of an antigen family. Because of this, the immunoassay of CEA by presently available methods is complicated by the fact that CEA is but one of several potentially reactive antigens. There have been at least sixteen CEA-like antigens described in the literature. Since some of these appear to be the same antigen described by different investigators, the actual number of different antigens is somewhat less than this number. Nonetheless, there is a complex array of cross-reactive antigens which can potentially interfere with an immunoassay of the CEA released by tumors. It is known that serum levels of CEA-like antigens are elevated in many non-cancerous conditions such an inflammatory liver diseases and also in smokers. It is important that immunoassays used for the monitoring of cancer patient status not be interfered with by these other CEA-like antigens. Conversely, it is important to be able to distinguish the antigens by immunoassays because of the possibility that different tumor types may preferentially express different forms of CEA. If so, then the ability of reliably measure the different forms of CEA can provide the means to diagnose or more successfully treat different forms of cancer. 
     The members of the &#34;CEA family&#34; share some antigenic determinants. These common epitopes are not useful in distinguishing the members of the antigen family and antibodies recognizing them are of little use for measuring tumor-specific CEA levels. 
     U.S. Pat. No. 3,663,684, entitled &#34;Carcinoembryonic Antigen and Diagnostic Method Using Radioactive Iodine&#34;, concerns purification and radioiodination of the CEA for use in a RIA. 
     U.S. Pat. No. 3,697,638 describes that CEA is a mixture of antigens (components A and B in this case). U.S. Pat. No. 3,697,638 mentions methods for separating and radioiodinating each component and their use in specific RIA&#39;s. 
     U.S. Pat. No. 3,852,415, entitled &#34;Compositions for Use in Radioimmunoassay, as Substitute for Blood Plasma Extract in Determination of Carcinoembryonic Antigen&#34; relates to the use of a buffer containing EDTA and bovine serum albumin as a substitute for plasma as a diluent for CEA RIA&#39;s. 
     U.S. Pat. No. 3,867,363, entitled &#34;Carcinoembryonic Antigens&#34;, is directed to the isolation of CEA components A and B, their labeling and use in a RIA. 
     U.S. Pat. No. 3,927,193, entitled &#34;Localization of Tumors by Radiolabelled Antibodies&#34;, concerns the use of radiolabelled anti-CEA antibodies in whole body tumor imaging. 
     U.S. Pat. No. 3,956,258, entitled &#34;Carcinoembryonic Antigens&#34;, relates to the isolation of CEA components A and B. 
     U.S. Pat. No. 4,086,217, entitled &#34;Carcinoembryonic Antigens&#34;, is directed to the isolation of CEA components A and B. 
     U.S. Pat. No. 4,140,753, entitled &#34;Diagnostic Method and Reagent&#34;, concerns the purification of a CEA isomer called CEA-S1 and its use in a RIA. 
     U.S. Pat. No. 4,145,336, entitled &#34;Carcinoembryonic Antigen Isomer&#34;, relates to the antigen CEA-S1. 
     U.S. Pat. No. 4,180,499, entitled &#34;Carcinoembryonic Antigens&#34;, describes a process for producing CEA component B. 
     U.S. Pat. No. 4,228,236, entitled &#34;Process of Producing Carcinoembryonic Antigen&#34;, is directed to the use of the established cell lines LS-174T and LS-180 or clones or derivatives thereof for the production of CEA. 
     U.S. Pat. No. 4,272,504, entitled &#34;Antibody Adsorbed Support Method for Carcinoembryonic Antigen Assay&#34;, concerns two concepts for the radioimmunoassay of CEA. First, U.S. Pat. No. 4,272,504 relates to a sample pretreatment in the form of heating to 65° to 85° C. at pH 5 to precipitate and eliminate extraneous protein. Second, it describes the use of a solid phase antibody (either on beads or tubes) as a means to capture analyte and radiolabelled CEA tracer. 
     U.S. Pat. No. 4,299,815, entitled &#34;Carcinoembryonic Antigen Determination&#34;, concerns diluting a CEA sample with water and pretreating by heating to a temperature below which precipitation of protein will occur. The pretreated sample is then immunoassayed using RIA, EIA, FIA or chemiluminescent immunoassay. 
     U.S. Pat. No. 4,349,528, entitled &#34;Monoclonal Hybridoma Antibody Specific for High Molecular Weight Carcinoembryonic Antigen&#34;, is directed to a monoclonal antibody reacting with 180 kD CEA, but not with other molecular weight forms. 
     U.S. Pat. No. 4,467,031, entitled &#34;Enzyme-Immunoassay for Carcinoembryonic Antigen&#34;, relates to a sandwich enzyme immunoassay for CEA in which the first of two anti-CEA monoclonal antibodies in attached to a solid phase and the second monoclonal is conjugated with peroxidase. 
     U.S. Pat. No. 4,489,167, entitled &#34;Methods and Compositions for Cancer Detection&#34;, describes that CEA shares an antigenic determinant with alpha-acid glycoprotein (AG), which is a normal component of human serum. The method described therein concerns a solid-phase sandwich enzyme immunoassay using as one antibody an antibody recognizing AG and another antibody recognizing CEA, but not AG. 
     U.S. Pat. No. 4,578,349, entitled &#34;Immunoassay for Carcinoembryonic Antigen (CEA)&#34;, is directed to the use of high salt containing buffers as diluents in CEA immunoassays. 
     EP 113072-A, entitled &#34;Assaying Blood Sample for Carcinoembryonic Antigen--After Removal of Interfering Materials by Incubation with Silica Gel&#34;, relates to the removal from a serum of a plasma sample of interfering substances by pretreatment with silica gel. The precleared sample is then subjected to an immunoassay. 
     EP 102008-A, entitled &#34;Cancer Diagnostics Carcinoembryonic Antigen--Produced from Perchloric Acid Extracts Without Electrophoresis&#34;, relates to a procedure for the preparation of CEA from perchloric acid extracts, without the use of an electrophoresis step. 
     EP 92223-A, entitled &#34;Determination of Carcinoembryonic Antigen in Cytosol or tissue--for Therapy Control and Early Recognition of Regression&#34;, concerns an immunoassay of CEA, not in serum or plasma, but in the cytosol fraction of the tumor tissue itself. 
     EP 83103759.6, entitled &#34;Cytosole-CEA-Measurement as Predictive Test in Carcinoma, Particularly Mammacarcinoma&#34;, is similar to EP 92223-A. 
     EP 83303759, entitled &#34;Monoclonal Antibodies Specific to Carcinoembryonic Antigen&#34;, relates to the production of &#34;CEA specific&#34; monoclonal antibodies and their use in immunoassays. 
     WO 84/02983, entitled &#34;Specific CEA-Family Antigens, Antibodies Specific Thereto and Their Methods of Use&#34;, is directed to the use of monoclonal antibodies to CEA-meconium (MA)-, and NCA-specific epitopes in immunoassays designed to selectively measure each of these individual components in a sample. 
     All of the heretofore CEA assays utilize either monoclonal or polyclonal antibodies which are generated by immunizing animals with the intact antigen of choice. None of them address the idea of making sequence specific antibodies for the detection of a unique primary sequence of the various antigens. They do not cover the use of any primary amino acid sequence for the production of antibodies to synthetic peptides or fragments of the natural product. They do not include the concept of using primary amino acid sequences to distinguish the CEA family members. None of them covers the use of DNA or RNA clones for isolating the genes with which to determine the primary sequence. 
     
         ______________________________________                DEFINITIONS______________________________________Nucleic Acid AbbreviationsA                      adenineG                      guanineC                      cytosineT                      thymidineU                      uracilAmino Acid Abbreviations:Asp                    aspartic acidAsn                    asparagineThr                    threonineSer                    serineGlu                    glutamic acidGln                    glutaminePro                    prolineGly                    glycineAla                    alanineCys                    cysteineVal                    valineMet                    methionineIle                    isoleucineLeu                    leucineTyr                    tyrosinePhe                    phenylalanineTrp                    tryptophanLys                    lysineHis                    histidineArg                    arginine______________________________________ 
    
     Nucleotide--A monomeric unit of DNA or RNA containing a sugar moiety (pentose), a phosphate, and a nitrogenous heterocyclic base. The base is linked to the sugar moiety via the glycosidic carbon (1&#39; carbon of the pentose) and that combination of base and sugar is called a nucleoside. The base characterizes the nucleotide. The four DNA bases are adenine (&#34;A&#34;), guanine (&#34;G&#34;), cytosine (&#34;C&#34;), and thymine (&#34;T&#34;). The four RNA bases are A, G, C and uracil (&#34;U&#34;). 
     DNA Sequence--A linear array of nucleotides connected one to the other by phosphodiester bonds between the 3&#39; and 5&#39; carbons of adjacent pentoses. 
     Functional equivalents--It is well known in the art that in a DNA sequence some nucleotides can be replaced without having an influence on the sequence of the expression product. With respect to the peptide this term means that one or more amino acids which have no function in a particular use can be deleted or replaced by another one. 
     Codon--A DNA sequence of three nucleotides (a triplet) which encodes through mRNA an amino acid, a translation start signal or a translation termination signal. For example, the nucleotide triplets TTA, TTG, CTT, CTC, CTA and CTG encode the amino acid leucine (&#34;Leu&#34;), TAG, TAA and TGA are translation stop signals and ATG is a translation start signal. 
     Reading Frame--The grouping of codons during translation of mRNA into amino acid sequences. During translation, the proper reading frame must be maintained. For example, the sequence GCTGGTTGTAAG may be translated in three reading frames or phases, each of which affords a different amino acid sequence ##STR1## 
     Polypeptide--A linear array of amion acids connected one to the other by peptide bonds between the alpha-amino and carboxy groups of adjacent amino acids. 
     Genome--The entire DNA of a cell or a virus. It includes inter alia the structural genes coding for the polypeptides of the cell or virus, as well as its operator, promoter and ribosome binding and interaction sequences, including sequences such as the Shrine-Dalgarno sequences. 
     Structural Gene--A DNA sequence which encodes through its template or messenger RNA (&#34;mRNA&#34;) a sequence of amino acids characteristic of a specific polypeptide. 
     Transcription--The process of producing mRNA rom a structural gene. 
     Translation--The process of producing a polypeptide from mRNA. 
     Expression--The process undergone by a structural gene to produce a polypeptide. It is a combination of transcription and translation. 
     Plasmid--A non-chromosomal double-stranded DNA sequence comprising an intact &#34;replicon&#34; such that the plasmid is replicated in a host cell. When the plasmid is placed within a unicellular organism, the characteristics of that organism may be changed or transformed as a result of the DNA of the plasmid. For example, a plasmid carrying the gene for tetracycline resistance (Tet®) transforms a cell previously sensitive to tetracycline into one which is resistant to it. A cell transformed by a plasmid is called a &#34;transformant&#34;. 
     Phage or Bacteriophage--Bacterial virus, many of which consist of DNA sequences encapsulated in a protein envelope or coat (&#34;capsid protein&#34;). 
     Cloning Vehicle--A palsmid, phage DNA or other DNA sequence which is capable of replicating in a host cell, which is characterized by one or a small number of endonuclease recognition sites at which such DNA sequences may be cut in a determinable fashion without attendant loss of an essential biological function of the DNA, e.g., replication, production of coat proteins or loss of promoter or binding sites, and which contains a marker suitable for use in the identification of transformed cells, e.g., tetracycline resistance or ampicillin resistance. A cloning vehicle is often called a vector. 
     Cloning--The process of obtaining a population of organisms of DNA sequences derived from one such organism or sequence by asexual reproduction. 
     Recombinant DNA Molecule or Hybrid DNA--A molecule consisting of segments of DNA from different genomes which have been joined end-to-end outside of living cells and have the capacity to infect some host cell and be maintained therein. 
     cDNA Expression Vector--A procaroytic cloning vehicle which also contains sequences of nucleotides that facilitate expression of cDNA sequences in eucaroytic cells. These nucleotides include sequences that function as eucaryotic promoter, alternative splice sites and polyadenylation signals. 
     Transformation/Transfection--DNA or RNA is introduced into cells in such a way as to allow gene expression. &#34;Infected&#34; referred to herein concerns the introduction of RNA or DNA by a viral vector into the host. 
     &#34;Injected&#34; referred to herein concerns the microinjection (use of a small syringe) of DNA into a cell. 
     CEA antigen family (CEA gene family)--a set of genes (gene family) and their products (antigen family) that share nucleotide sequences homologous to partial cDNA LV-7 (CEA-(a)) and as a result of theses similarities also share a subset of their antigenic epitopes. Examples of the CEA antigen family include CEA (=CEA-(b)), transmembrane CEA (TMCEA)=CEA-(c) and normal crossreacting antigen NCA (=CEA-(d)). 
     SUMMARY OF THE INVENTION 
     The present invention concerns the following DNA sequences designated as TM-2 (CEA-(e)), TM-3 (CEA-(f)), TM-4 (CEA-(g)), KGCEA1 and KGCEA2, which code for CEA antigen family peptide sequences or nucleic acids having a base sequence (DNA or RNA) that are hybridizable therewith: ##STR2## which has been designated SEQ ID No:5 and SEQ ID No:13 for the translated polypeptide. ##STR3## which has been designated SEQ ID No:6 and SEQ ID No:14 for the translated polypeptide. ##STR4## which has been designated SEQ ID No:7 and SEQ ID No:15 for the translated polypeptide. 
     The present invention is also directed to a replicable recombinant cloning vehicle (&#34;vector&#34;) having an insert comprising a nucleic acid, e.g., DNA, which comprises a base sequence which codes for a CEA peptide or a base sequence hybridizable therewith. 
     This invention also relates to a cell that is transformed/transfected, infected or injected with the above described replicable recombinant cloning vehicle or nucleic acid hybridizable with the aforementioned cDNA. Thus the invention also concerns the transfection of cells using free nucleic acid, without the use of a cloning vehicle. 
     Still further, the present invention concerns a polypeptide expressed by the above described transfected, infected or injected cell, which polypeptide exhibits immunological cross-reactivity with a cEA, as well as labelled forms of the polypeptide. The invention also relates to polypeptides having an amino acid sequence, i.e., synthetic peptides, or the expression product of a cell that is transfected, injected, infected with the above described replicable recombinant cloning vehicles, as well as labelled forms thereof. Stated otherwise, the present invention concerns a synthetic peptide having an amino acid sequence corresponding to the entire amino acid sequence or a portion thereof having no less than five amion acids of the aforesaid expression product. 
     The invention further relates to an antibody preparation specific for the above described polypeptide. 
     Another aspect of the invention concerns an immunoassay method for detecting CEA or a functional equivalent thereof in a test sample comprising 
     (a) contacting the sample with the above described antibody preparation, and 
     (b) determining binding thereof to CEA in the sample. 
     The invention also is directed to a nucleic acid hybridization method for detecting a CEA or a related nucleic acid (DNA or RNA) sample in a test sample comprising 
     (a) contacting the test sample with a nucleic acid probe comprising a nucleic acid, which comprises a base sequence which codes for a CEA peptide sequence or a base sequence that is hybridizable therewith, and 
     (b) determining the formation of the resultant hybridized probe. 
     The present invention also concerns a method for detecting the presence of carcinoembryonic antigen or a functional equivalent thereof in an animal or human patient in vivo comprising 
     a) introducing into said patient a labeled (e.g., a radio-opaque material that can be detected by X-rays, radiolabeled or labeled with paramagnetic materials that can be detected by NMR) antibody preparation according to the present invention and 
     b) detecting the presence of such antibody preparation in the patient by detecting the label. 
     In another aspect, the present invention relates to the use of an antibody preparation according to the present invention for therapeutic purposes, namely, attaching to an antibody preparation radionuclides, toxins or other biological effectors to form a complex and introducing an effective amount of such complex into an animal or human patient, e.g., by injection or orally. The antibody complex would attach to CEA in a patient and the radionuclide, toxin or other biological effector would serve to destroy the CEA expressing cell. 
    
    
     BRIEF DESCRIPTION OF THE DRAWINGS 
     FIG. 1 consists of four schematic representations (FIGS. 1A-1D) of the transmembrane CEA&#39;s, wherein: 
     FIG. 1A is a schematic representation of TM1 (CEA-(c)); 
     FIG. 1B is a schematic representation of TM2 (CEA-(e)); 
     FIG. 1C is a schematic representation of TM3 (CEA-(f)); and 
     FIG. 1D is a schematic representation of TM4 (CEA-(g)). 
    
    
     DETAILED DESCRIPTION OF THE INVENTION 
     In parent applications, applicants described the following CEA&#39;s: 
     
         ______________________________________                 ATCC No.______________________________________CEA-(a)   partial CEA (pcLV7)CEA-(b)   full coding CEA (pc 15LV7)                       67709CEA-(c)   TM-1 (FL-CEA; pc 19-22)                       67710CEA-(d)   NCA (pcBT 20)     67711______________________________________ 
    
     In the present application, applicants described the following CEA&#39;s: 
     
         ______________________________________                 ATCC No.______________________________________CEA-(e)   TM-2 (pc E22)     67712CEA-(f)   TM-3 (pc HT-6)    67708CEA-(g)   TM-4.______________________________________ 
    
     ATCC Nos. 67708, 67709, 67710, 67711 and 67712 were all deposited with the America Type Culture Collection on May 25, 1988. 
     The sequences for CEA-(a), CEA-(b), CEA-(c) and CEA-(d) are given hereinbelow: CEA-(a): 
     
         __________________________________________________________________________GG   GGT TTA CAC AAC CAC CAC CCC ATC AAA CCC TTC ATC ACC AGC AAC AAC TCCAAC CCC GTGGAG GAT GAG GAT GCT GTA GCC TTA ACC TGT GAA CCT GAG ATT CAG AAC ACAACC TAC CTGTGG TGG GTA AAT AAT CAG AGC CTC CCG GTC AGT CCC AGG CTG CAG CTG TCCAAT GAC AACAGG ACC CTC ACT CTA CTC AGT GTC ACA AGG AAT GAT GTA GGA CCC TAT GAGTGT GGA ATCCAG AAC GAA TTA AGT GTT GAC CAC AGC GAC CCA GTC ACC CAG CGA TTC CTCTAT GGC CCAGAC GAC CCC ACC ATT TCC CCC TCA TAC ACC TAT TAC CGT CCA GGG GTG GAAOCT CAG CCTCTC TGC CAT GCA GCC TCT AAC CCA CCT GCA CAG TAT TCT TGG CTG ATT GATGGG ACC GTCCAG CAA CAC ACA CAA GAG CTC TTT ATC TCC AAC ATC ACT GAG AAG AAC AGCGGA CTC TATACC TGC CAG GCC AAT AAC TCA GCC AGT GGC ACA GCA GGA CTA CAG TCA AGACAA TCA CAGTCT CTG CGG ATG CCC AAG CCC TCC ATC TCC AGC AAC AAC TCC AAA CCC GTGGAG GAC AAGGAT CGC TGT GGC CTT CAC TGT GAA CCT GAG GCT CAG AAC ACA ACC TAC CTGTGG TGG GTAAAT GGT CAG AGC CTC CCA GTC AGT CCC AGG CTG CAG CTG TCC AAT GGC AACAGG ACC CTCACT CTA TTC AAT GTC ACA AGA AAT GAC GCA AGA GCC TAT GTA TGT GGA ATCCAG AAC TCAGTG AGT GCA AAC CGC AGT GAC CCA GTC ACC CTG GAT GTC CTC TAT GGG CCGGAC ACC CCCATC ATT TCC CCC CCC CC__________________________________________________________________________ 
    
     which has been designated SEQ ID No:1. ##STR5## which has been designated SEQ ID No.2 and SEQ ID No:10 for the translated polypeptide. ##STR6## which has been designated SEQ ID No.3 and SEQ ID No:11 for the translated polypeptide. ##STR7## which has been designated SEQ ID No.4 and SEQ ID No:12 for the translated polypeptide. 
     A schematic relationship of th transmembrane CEA&#39;s, namely TM-1 (CEA-(c)), TM-2 (CEA-(e)), TM-3 (CEA-(f)) and TM-4 (CEA-(g)) is depicted in FIG. 1: 
     Assuming TM-1 is composed of five sections as depicted in FIG. 1, namely 10, 12, 14, 16 and 18, TM-2 differs from TM-1 in that the 100 amino acid (100 AA) section 14 is deleted and at splice point 20 between sections 12 and 16, surprisingly an extra amino acid, namely Asp occurs. 
     TM-3 is the same as TM-1 except that section 18 is truncated at splice point 22, i.e., a section of 70 amino acids is deleted and results in a new section made up of subsections 24+26. Surprisingly, however, six new amino acids (section 26) occur. Another example of formation of a novel amino acid sequence resulting from a deletion of nucleic acid sequence is for platelet derived growth factor-A. 
     TM-4 is the same as TM-2 up until the end of subsection 24. 
     Subsection 24 is contained in section 18 of TM-1 and TM-2, but is not depicted in FIG. 1 for TM-1 and TM-2. 
     Some CEA epitopes are unique. These are the epitopes which have been useful for distinguishing the various CEA-like antigens immunologically. Peptide epitopes are defined by the linear amino acid sequence of the antigen and/or features resulting from protein folding. The information required for protein folding is encoded in the primary amino acid sequence. Therefore, antigenic differences ultimately result from differences in the primary structure of the different CEA molecules. The differences residing in the CEA protein in the CEA species can thus be determined by determining the primary amino acid sequences. This can be most readily accomplished by cloning and sequencing each of the genes for CEA. To determine which gene products will be most useful for cancer diagnosis, unique probes can be selected from each gene and expression of each gene can be determined in different tumor types by nucleic acid hybridization techniques. The present invention provides a tool with which to identify potential genes coding for different members of the CEA family and to determine the theoretical primary amino acid sequences for them. Using the method of automated peptide synthesis, peptides can then be synthesized corresponding to unique sequences in these antigens. With these peptides, antibodies to these sequences can be produced which, in the intact CEA molecule, might not be recognized by the animal being immunized. Having accomplished this, advantage can then be taken of the differences in these antigens to generate specific immunoassays for the measurement of each antigen. 
     A wide variety of host/cloning vehicle combinations may be employed in cloning the double-stranded nucleic acid prepared in accordance with this invention. For example, useful cloning vehicles may consist of segments of chromosomal, non-chromosomal and synthetic DNA sequences, such as various known derivatives of SV40 and known bacterial plasmids, e.g., plasmids from E. coli including col E1, pCR1, pBR322, pMB89 and their derivatives, wider host range plasmids, e.g., RP4, and phage DNAs, e.g., the numerous derivatives of phage, e.g., NM989, and other DNA phages, e.g., M13 and Filamenteous single-stranded DNA phages and vectors derived from combinations of plasmids and phage DNAs such as plasmids which have been modified to employ phage DNA or other expression control sequences or yeast plasmids such as the 2 μplasmid or derivatives thereof. Useful hosts may include bacterial hosts such as strains of E. coli, such as E. coli HB 101, E. coli X1776, E. coli X2282, E. coli MRC1 and strains of Pseudomonas, Bacillus subtilis, Bacillus stearothermophilus and other E. coli, bacilli, yeasts and other fungi, animal or plant hosts such as animal (including human) or plant cells in culture or other hosts. Of course, not all host/vector combinations may be equally efficient. The particular selection of host/cloning vehicle combination may be made by those of skill in the art after due consideration of the principles set forth without departing from the scope of this invention. 
     Furthermore, within each specific cloning vehicle, various sites may be selected for insertion of the nucleic acid according to the present invention. These sites are usually designated by the restriction endonuclease which cuts them. For example, in pBR322 the Pstl site is located in the gene for beta-lactamase, between the nucleotide triplets that code for amino acids 181 and 182 of that protein. One of the two HindII endonuclease recognition sites is between the triplets coding for amino acids 101 and 102 and one of the several Taq sites at the triplet coding for amino acid 45 of beta-lactamase in pBR322. In similar fashion, the EcoRI site and the PVUII site in this plasmid lie outside of any coding region, the EcoRl site being located between the genes coding for resistance to tetracycline and ampicillin, respectively. These sites are well recognized by those of skill in the art. It is, of course, to be understood that a cloning vehicle useful in this invention need not have a restriction endonuclease site for insertion of the chosen DNA fragment. Instead, the vehicle could be cut and joined to the fragment by alternative means. 
     The vector or cloning vehicle and in particular the site chosen therein for attachment of a selected nucleic acid fragment to form a recombinant nucleic acid molecule is determined by a variety of factors, e.g., the number of sites susceptible to a particular restriction enzyme, the size of the protein to be expressed, the susceptibility of the desired protein to proteolytic degradation by host cell enzymes, the contamination of the protein to be expressed by host cell proteins difficult to remove during purification, the expression characteristics, such as the location of start and stop codons relative to the vector sequences, and other factors recognized by those of skill in the art. The choice of a vector and an insertion site for a particular gene is determined by a balance of these factors, not all sections being equally effective for a given case. 
     Methods of inserting nucleic acid sequences into cloning vehicles to form recombinant nucleic acid molecules include, for example; da-dT tailing, direct ligation, synthetic linkers, exonuclease and polymerase-linked repair reactions followed by ligation, or extension of the nucleic acid strand with an appropriate polymerase and an appropriate single-stranded template followed by ligation. 
     It should also be understood that the nucleotide sequences or nucleic acid fragments inserted at the selected site of the cloning vehicle may include nucleotides which are not part of the actual structural gene for the desired polypeptide or mature protein or may include only a fragment of the complete structural gene for the desired protein or mature protein. 
     The cloning vehicle or vector containing the foreign gene is employed to transform an appropriate host so as to permit that host to replicate the foreign gene and to express the protein coded by the foreign gene or portion thereof. The selection of an appropriate host is also controlled by a number of factors recognized by the art. These include, for example, the compatibility with the chosen vector, the toxicity of proteins encoded by the hybrid plasmid, the ease of recovery of the desired protein, the expression characteristics, biosafety and costs. A balance of these factors must be struck with the understanding that not all hosts may be equally effective for expression of a particular recombinant DNA molecule. 
     The level of production of a protein is governed by two major factors: the number of copies of its gene within the cell and the efficiency with which these gene copies are transcribed and translated. Efficiency of transcription and translation (which together comprise expression) is in turn dependent upon nucleotide sequences, normally situated ahead of the desired coding sequence. These nucleotide sequences or expression control sequences define inter alia, the location at which RNA polymerase interacts to initiate transcription (the promoter sequence) and at which ribosomes bind and interact with the mRNA (the product of transcription) to initiate translation. Not all such expression control sequences function with equal efficiency. It is thus of advantage to separate the specific coding sequences for the desired protein from their adjacent nucleotide sequences and fuse them instead to other known expression control sequences so as to favor higher levels of expression. This having been achieved, the newly engineered nucleic acid, e.g., DNA, fragment may be inserted into a multicopy plasmid or a bacteriophage derivative in order to increase the number of gene copies within the cell and thereby further improve the yield of expressed protein. 
     Several expression control sequences may be employed as described above. These include the operator, promoter and ribosome binding and interaction sequences (including sequences such as the Shine-Dalgarno sequences) of the lactose operon of E. coli (&#34;the lac system&#34;), the corresponding sequences of the tryptophan synthetase system of E. coli (&#34;the trp system&#34;), the major operator and promoter regions of phase λ(O L  P L  and O R  P&#39; R ), the control region of Filamenteous singlestranded DNA phages, or other sequences which control the expression of genes of prokaryotic or eukaryotic cells and their viruses. Therefore, to improve the production of a particular polypeptide in an appropriate host, the gene coding for that polypeptide may be selected and remove from a recombinant nucleic acid molecule containing it and reinserted into a recombinant nucleic acid molecule closer or in a more appropriate relationship to its former expression control sequence or under the control of one of the above described expression control sequences. Such methods are known in the art. 
     As used herein &#34;relationship&#34; may encompass many factors, e.g., the distance separating the expression enhancing and promoting regions of the recombinant nucleic acid molecule and the inserted nucleic acid sequence, the transcription and translation characteristics of the inserted nucleic acid sequence or other sequences in the vector itself, the particular nucleotide sequence of the inserted nucleic acid sequence and other sequences of the vector and the particular characteristics of the expression enhancing and promoting regions of the vector. 
     Further increases in the cellular yield of the desired products depend upon an increase in the number of genes that can be utilized in the cell. This is achieved, for illustration purposes, by insertion of recombinant nucleic acid molecules engineered into the temperature bacteriophage λ(NM989), most simply by digestion of the plasmid with a restrictive enzyme, to give a linear molecule which is then mixed with a restricted phage λ cloning vehicle (e.g., of the type described by N. E. Murray et al, &#34;Lambdoid Phages That Simplify the Recovery of In Vitro Recombinants&#34;, Molec. Gen. Genet., 150, pp. 53-61 (1977) and N. E. Murray et al. &#34;Molecular Cloning of the DNA Ligase Gene From Bacteriophage T4&#34;, J. Mol. Biol., 132, pp. 493-505 (1979)) and the recombinant DNA molecule recircularized by incubation with DNA ligase. The desired recombinant phage is then selected as before and used to lysogenize a host strain of E. coli. 
     Particularly useful λ cloning vehicles contain a temperature-sensitive mutation in the repression gene cl and suppressible mutations in gene S, the product of which is necessary for lysis of the host cell, and gene E, the product of which is major capsid protein of the virus. With this system, the lysogenic cells are grown at 32° C. and then heated to 45° C. to induce excision of the prophage. Prolonged growth at 37° C. leads to high levels of production of the protein, which is retained within the cells, since these are not lysed by phage gene products in the normal way, and since the phage gene insert is not encapsulated it remains available for further transcription. Artificial lysis of the cells then releases the desired product in high yield. 
     In addition, it should be understood that the yield of polypeptides prepared in accordance with this invention may also be improved by substituting different codons for some or all of the codons of the present DNA sequences, these substituted codons coding for amino acids identical to those coded for the codons replaced. 
     Finally, the activity of the polypeptides produced by the recombinant nucleic acid molecules of this invention may be improved by fragmenting, modifying or derivatizing the nucleic acid sequences or polypeptides of this invention by well-known means, without departing from the scope of this invention. 
     The polypeptides of the present invention include the following: 
     (1) the polypeptides expressed by the above described cells, 
     (2) polypeptides prepared by synthetic means, 
     (3) fragments of polypeptides (1) or (2) above, such fragments produced by synthesis of amino acids or by digestion or cleavage. 
     Regarding the synthetic peptides according to the invention, chemical synthesis of peptides is described in the following publications: S. B. H. Kent, Biomedical Polymers, eds. Goldberg, E. P. and Nakajima, A. (Academic Press, New York), 213-242, (1980); A. R. Mitchell, S. B. H. Kent, M. Engelhard and R. B. Merrifield, J. Org. Chem., 43, 2845-2852, (1978); J. P. Tam, T. -W. Wong, M. Riemen, F. -S. Tjoeng and R. B. Merrifield, Tet. Letters, 4033-4036, (1979); S. Mojsov, A. R. Mitchell and R. B. Merrifield, J. Org. Chem., 45, 555-560, (1980); J. P. Tam, R. D. DiMarchi and R. B. Merrifield, Tet. Letters, 2851-2854, (1981); and S. B. H. Kent, M. Riemen, M. Le Doux and R. B. Merrifield, Proceedings of the IV International Symposium on Methods of Protein Sequence Analysis, (Brookhaven Press, Brookhave, N.Y.), in press, 1981. 
     In the Merrifield phase procedure, the appropriate sequence of L-amino acids ia guilt up from the carboxyl terminal amino acid to the amino terminal amino acid. Starting with the appropriate carboxyl terminal amino acid attached to a polystyrene (or other appropriate) resin via chemical linkage to a chloromethyl group, benzhydrylamine group, or other reactive group of the resin, amino acids are added by one using the following procedure. The peptide-resin is: 
     (a) washed with methylene chloride; 
     (b) neutralized by making for 10 minutes at room temperature with 5% (v/v) diisopropylethylamine (or other hindered base) in methylene chloride; 
     (c) washed with methylene chloride; 
     (d) an amount of amino acid equal to six times the molar amount of the growing peptide chain is activated by combining it with one-half as many moles of a carbodiimide (e.g., dicyclohexylcarbodiimide, or diisopropylcarbodiimide) for ten minutes at 0° C., to form the symmetric anhydride of the amino acid. The amino acid used should be provided originally as the N-alpha-tert.-butyloxycarbonyl derivative, with side chains protected with benzyl esters (e.g., aspartic or glutamic acids), benzyl ethers (e.g., serine, threonine, cysteine or tyrosine), benzyloxycarbonyl groups (e.g., lysine) or other protecting groups commonly used in peptide synthesis; 
     (e) the activated amino acid is reacted with the peptide-resin for two hours at room temperature, resulting in addition of the new amino acid to the end of the growing peptide chain; 
     (f) the peptide-resin is washed with methylene chloride; 
     (g) the N-alpha-(tert.-butyloxycarbonyl) group is removed from the most recently added amino acid by reacting with 30 to 65%, preferably 50% (v/v) trifluoroacetic acid in methylene chloride for 10 to 30 minutes at room temperature; 
     (h) the peptide-resin is washed with methylene chloride; 
     (i) steps (a) through (h) are separated until the required peptide sequence has been constructed. 
     The peptide is then removed from the resin and simultaneously the side-chain protecting groups are removed, by reaction with anhydrous hydrofluoric acid containing 10% v/v of anisole or other suitable (aromatic) scavenger. Subsequently, the peptide can be purified by gel filtration, ion exchange, high pressure liquid chromatography, or other suitable means. 
     In some cases, chemical synthesis can be carried out without the solid phase resin, in which case the synthetic reactions are performed entirely in solution. The reactions are similar and well known in the art, and the final product is essentially identical. 
     Digestion of the polypeptide can be accomplished by using proteolytic enzymes, especially those enzymes whose substrate specificity results in cleavage of the polypeptide at sites immediately adjacent to the desired sequence of amino acids. 
     Cleavage of the polypeptide can be accomplished by chemical means. Particular bonds between amino acids can be cleaved by reaction with specific reagents. Examples include the following: bonds involving methionine are cleaved by cyanogen bromide; asparaginyl-glycine bonds are cleaved by hydroxylamine. 
     The present invention has the following advantages: 
     (1) The nucleic acids coding for TM-1, Tm-2 and TM-3 can be used as probes to isolate other members of the CEA gene family. 
     (2) The nucleic acids coding for TM-1, TM-2 and TM-3 can be used to derive oligonucleotide probes to determine the expresssion of TM-1, TM-2, TM-3 and other CEA genes in various tumor types. 
     (3) TM-1, TM-2, TM-3 and TM-4 nucleotide sequences can be used to predict the primary amino acid sequence of the protein for production of synthetic peptides. 
     (4) Synthetic peptides derived from the above sequences can be used to produce a sequence-specific antibodies. 
     (5) Immunoassays for each member of the CEA antigen family can be produced with these sequence-specific antibodies and synthetic peptides. 
     (6) The aforementioned immunoassays can be used as diagnostics for different types of cancer if it is determined that different members of the CEA family are clinically useful markers for different types of cancer. 
     Peptides according to the present invention can be labelled by conventional means using radioactive moieties (e.g.,  125  I), enzymes, dyes and fluorescent compounds, just to name a few. 
     Several possible configurations for immunoassays according to the present invention can be used. The readout systems capable of being employed in these assays are numerous and non-limiting examples of such systems include fluorescent and colorimetric enzyme systems, radioisotopic labelling and detection and chemiluminescent systems. Two examples of immunoassay methods are as follows: 
     (1) An enzyme linked immunoassay (ELISA) using an antibody preparation according to the present invention (including Fab or F(ab)&#39; fragments derived therefrom) to a solid phase (such as a microtiter plate or latex beads) is attached a purified antibody of a specificity other than that which is conjugated to the enzyme. This solid phase antibody is contacted with the sample containing CEA antigen family members. After washing, the solid phase antibody-antigen complex is contacted with the conjugated anti-peptide antibody (or conjugated fragment). After washing away unbound conjugate, color or fluorescence is developed by adding a chromogenic or fluorogenic substrate for the enzyme. The amount of color or fluorescence developed is proportional to the amount of antigen in the sample. 
     (2) A competitive fluorometric immunoassay using fluorescently labelled peptide or synthetic peptides of the sequences for TM-2, TM-2, TM-3 and TM-4. In this example, the purified peptide expressed by cells or synthetic peptides thereof are fluorescently labelled. To a solid phase is attached a purified antibody. This solid phase is then contacted with sample containing CEA antigen family members to which has been added fluorescent peptide probe. After binding, excess probe is washed away the amount of bound probe is quantitated. The amount of bound fluorescent probe will be inversely proportional to the amount of antigen in the sample. 
     In the nucleic acid hybridization method according to the present invention, the nucleic acid probe is conjugated with a label, for example, an enzyme, a florophore, a radiostope, a chemiluminescent compound, etc. In the most general case, the probe would be contacted with the sample and the presence of any hybridizable nucleic acid sequence would be detected by developing in the presence of a chromogenic enzyme substrate, detection of the fluorophore by epifluorescence, by autoradiography of the radioisotopically labelled probe or by chemiluminescence. The detection of hybridizable RNA sequences can be accomplished by (1) a dot blot methodology or (2) an in situ hybridization methodology. Methods of these last two techniques are described by D. Gillespie and J. Bresser, &#34;mRNA Immobilization in NaI: Quick Blots&#34;, Biotechniques, 184-192, November/December 1983 and J. Lawrence and R. Singer, &#34;Intracellular Localization of Messenger RNAs for Cytosketal Proteins&#34;, Cell, 45, 407-415, May 9, 1986, respectively. The readout systems can be the same as described above, e.g., enzyme labelling, radiolabelling, etc. 
     As stated above, the invention also relates to the use in medicine of the aforementioned complex of the invention. 
     The invention further provides a pharmaceutical composition containing as an active ingredient a complex of the invention in the form of a sterile and/or physiologically isotonic aqueous solution. 
     For parenteral administration, solutions and emulsions containing as an active ingredient the complex of the invention should be sterile and, if appropriate, blood-isotonic. 
     It is envisaged that the active complex will be administered perorally, parenterally (for example, intramuscularly, intraperitoneally, or intravenously), rectally or locally. 
     EXAMPLE 1 
     Preparation of cDNA in pCE22 which codes for TM2-CEA [CEA-(e)) 
     Example 1a 
     RNA Preparation 
     Messenger RNA was prepared by the proteinase K extraction method of J. Favolaro, R. Treisman and R. Kamen, Methods in Enzymology, 65, 718, Academic Press, Inc. (1980), followed by olido dT cellulose chromatography to yield poly A+ RNA (3&#39;-polyadenylated eukaryotic RNA containing most mRNA sequences that can be translated into polypeptides). To obtain approximately 100 μg of poly A+ RNA, approximately ×10 8  cells of transfectant 23.411 (ATCC No. CRL 9731, deposited with the ATCC on Jun. 1, 1988), that expresses TM-1, TM-2, TM-3 and TM-4, Kamarck et al, Proc. Natl. Acad. Sci., USA, 84, 5350-5354, August 1987, were harvested from roller bottles after late logarithmic growth. Cells were lysed by homogenization in an ice-cold solution of 140 mM NaCl, 1.5 mM MgCl 2 , 10 mM Tris-HCl, pH 8.0, 0.5% NP40, 4 mM dithiothreitol and 20 units of placental ribonuclease inhibitor/ml. sodium deoxycholate was then added to 0.2 %. Cytoplasm and nuclei were separated by centrifugation of the homogenate at 12,000×g for 20 minutes. The cytoplasmic fraction was mixed with an equal volume of 0.2 M Tris-HCl, pH 7.8, 25 mM EDTA, 0.3 M NaCl, 2% sodium dodecyl sulfate and 400 μg/ml of proteinase K, incubated for 1 hour at 37° C., then extracted once with an equal volume of phenol/chloroform (1:1/v:v) solution. Nucleic acids were obtained by ethanol precipitation of the separated aqueous phase. Total RNA was enriched by passage in 0.5 M NaCl, 10 mM Tris-HCl, pH 7.8, 0.1% sarcosyl through an oligo dT(12-18) cellulose column. After washing, bound RNA was eluted in the same solution without sodium chloride. 
     Example 1b 
     Reverse Transcription of mRNA 
     Ten micrograms of poly A+ RNA were primed for reverse transcription with oligo dT(12-18) and pdN 6  primers. One hundred microliter reaction was performed for 4 hours at 42° C. with 200 units AMV reverse transcriptase (Life Science, Inc. St. Petersburg, Fla., U.S.A.). The RNA component of the cDNA/mRNA hybrids was replaced with the second complementary strand by treatment with RTNase H, E. coli DNA polymerase I and E. coli DNA ligase at 12° C. and 22° C. for 1.5 hours each. Molecular ends were polished by treatment with T4 DNA polymerase. cDNA was phenol/chloroform extracted and purified over a &#34;SEPHADEX G-50&#34; spun column prepared in 10 mM Tris-HCl, pH 7.8, 1 mM EDTA (TE). 
     Example 1c 
     Cloning of pcE22 (plasmid cDNA E22) 
     Synthetic DNA linkers ##STR8## were attached to the ends of cDNA by blunt end ligation with excess T4 DNA ligase. Excess linkers were removed by chromatography through &#34;SEPHADEX G-50&#34; (medium) in TE, and by fractionation of 0.8% low melting agarose gel. Based on Northern blot analysis of poly A+ RNA of the 23.411 cell line, the size of the CEA-related mRNA was estimated at 3.6 kb. Therefore, cDNA fragments between 2 and 4 kb were recovered from gel slices and fragments were ethanol precipitated. After resuspension of cDNA in TE, EcoRI-cleaved lambda gt10 arms were added to cDNA at an estimated molar ratio of 1:1. Ligation proceeded at 7° C. for 2 days in the presence of T4 DNA ligase. Aliquots of the ligation reaction were added to commercially-obtained packaging mix (Stratagene, San Diego, Calif., U.S.A.). Five million phage particles were obtained ofter in vitro packaging and infection of E. coli host NM514. 
     Example 1d 
     Screening of Recombinant Library 
     Five hundred thousand packaged lambda particles were plated on lawns of E. coli NM514 and replicate patterns were lifted onto nitrocellulose sheets as described by W. D. Benton and R. W. Davis, Science 196, 180-182, (1977). Positive phase were selected by hybridization with  32  P-labeled LV7 cDNA insert probe that contained a domain repeated amoung various CEA family members. By multiple rounds of screening. Phage from individual plaques were amplified and titered, and these were used to prepare small quantities of recombinant phage DNA. 
     Example 1e 
     DNA Manipulation 
     Phage DNA was prepared according to T. Maniatis, E. Fritsch and J. Sambrook, Molecular Cloning, A Laboratory Manual, Cold Spring Habor, (1982). DNA segments were isolated from low melting agarose gels and inserted for subcloning into Bluescript plasmid vectors (Stratagene, San Diego, Calif., U.S.A.). DNA sequencing was performed by the dideoxy termination method of F. Sanger, S. Nicklen and A. Coulson, Proc. Natl. Acad. Sci., U.S.A., 74, 5463-5467, (1977). The nucleic acid and translated sequence for cDNA in pcE22 is given hereinabove (TM-2(CEA-(e)). 
     EXAMPLE 2 
     Preparation of cDNA in pcHT-6 which Partically Codes TM3-CEA [CEA-(f)] 
     Example 2a 
     RNA Preparation 
     Messenger RNA was prepared by the proteinase K extraction method of J. Favolaro, R. Treismand and R. Kamen, Methods in Enzymology, 65 718, Academic Press, Inc. (1980), followed by oligo dT cellulose chromatography to yield poly A+ RNA (3&#39;-polyadenylated eukaryotic RNA containing most mRNA sequences that can be translated into polypeptides). To obtain approximately 100 ug of poly A+ RNA, approximately 3×10 8  cells of HT-29 tumor cells (ATCC HTB38) were harvested form roller bottles after late logarithmic growth. Cells were lysed by homogenization in an ice-cold solution of 140 mM NaCl, 1.5 mM MgCl 2 , 10 mM Tri-HCl, pH 8.0, 0.5% NP40, 4 mM dithiothreitol and 20 units of placental ribonuclease inhibitor/ml. Sodium deoxycholate was then added to 0.2 %. Cytoplasm and nuclei were separated by centrifugation of the homogenate at 12,000×g for 20 minutes. The cytoplasmic fraction was mixed with an equal volume of 0.2 M Tris-Hcl, pH 7.8, 25 mM EDTA, 0.3  M NaCl, 2% sodium dodecyl sulfate and 400 μg/ml of proteinase K, incubated for 1 hour at 37° C., then extracted once with an equal volume of phenol/chloroform (1:1/v:v) solution. Nucleic acids were obtained by ethanol precipitation of the separated aqueous phase. Total RNA was enriched by passage in 0.5 M NaCl, 10 mM Tris-HCl, pH 7.8, 0.1% sarcosyl through an oligo dT(12-18) cellulose column. After washing, bound RNA was eluted in the same solution without sodium chloride. 
     Example 2b 
     Reverse Transcription of mRNA 
     Ten microgram of HT-29 poly A+ RNA were primed for reverse transcription with olido dT(12-18) and pdN 6  primers. One hundred microliter reaction was performed for 4 hours at 42° C. with 200 units AMV reverse transcriptase (Life Science, Inc. St. Petersburg, Fla., U.S.A.). The RNA component of the cDNA/mRNA hybrids was replaced with the second complementary strand by treatment with RNase H, E. coli DNA polymerase I and E. coli DNA ligase at 12° C. and 22° C. for 1.5 hours each. Molecular ends were polished by treatment with T4 DNA polymerase. cDNA was phenol/chloroform extracted and purified over a &#34;SEPHADEX G-50&#34; spun column prepared in 10 mM Tris-HCl, pH 7.8, 1 mM EDTA (TE). 
     Example 2c 
     Cloning of pcHT-6 (plasmid cDNA HT-6) 
     Synthetic DNA linkers ##STR9## were attached to the ends of cDNA by blunt end ligation with excess T4 DNA ligase. Excess linkers were removed by chromatography through &#34;SEPHADEX G-50&#34; (medium) in TE, and by fractionation on 0.8% low melting agarose gel. Based on Northern blot analysis of poly A+ RNA of the HT-29 cell line, the size of the CEA-related mRNA was estimated at 2.2 kb. Therefore, cDNA fragments between 2 and 3 kb were recovered from gel slices and fragments were ethanol precipitated. After resuspension of cDNA in TE, EcoRI-cleaved lambda gt10 arms were added to cDNA at an estimated molar ratio of 1:1. Ligation proceeded at 7° C. for 2 days in the presence of T4 DNA ligase. Aliquots of the ligation reaction were added to commercially-obtained packaging mix (Stratagene, San Diego, Calif., U.S.A.). Five million phage particles were obtained often in vitro packaging and infection of E. coli host NM514. 
     Example 2d 
     Screening of Recombinant Library 
     Five hundred thousand packaged lambda particles were plated on lawns of E. coli NM514 and replicate patterns were lifted onto nitrocellulose sheets as described by W. D. Benton and R. W. David, Science, 196, 180-182, (1977). Positive phage were selected by hybridization with  32  P-labeled LV7 cDNA insert probe that contained a domain repeated amoung various CEA family members. By multiple rounds of screening. Phage from individual plaques were amplified and titered, and these were used to prepare small quantities of recombinant phage DNA. 
     Example 2e 
     DNA Manipulation 
     Phage DNA was prepared according to T. Maniatis, E. Fritsch and J. Sambrook, Molecular Cloning, A Laboratory Manual, Cold Spring Habor, (1982). DNA segments were isolated from low melting agarose gels and inserted for subcloning into Bluescript plasmid vectors (Stratagene, San Diego, Calif., U.S.A.). DNA sequencing was performed by the dideoxy termination method of F. Sanger, S. Nicklen and A. Coulson, Proc. Natl. Acad. Sci., U.S.A., 74, 5463-5467, (1977). The nucleic acid and translated sequence for cDNA in HT-6 not complete at the 5&#39; end of its coding region, but the nucleotide sequence and restriction map of the HT-6 inset indicates that it is related to nucleic acid sequences of cDNA clones coding for CEA-(c) and CEA-(e). The nucleotide sequence of HT-6 insert differs from these clones at only nucleotide position 1463 to 1515 and 1676 to 2429 of the CEA-(c) cDNA. It is inferred from this result that the pcHT-6 insert is a partial coding sequence for CEA-(f) and the presumed nucleic acid and translated sequence of CEA-(f) is given hereinabove (TM-3 (CEA-(f)). 
     EXAMPLE 3 
     Preparation of cDNA which codes for TM4-CEA [CEA-(g)] 
     Example 3a 
     RNA Preparation 
     Messenger RNA is prepared by the proteinase K extraction method of J. Favolaro, R. Treisman and R. Kamen, Methos in Enzymology, 65, 718, Academic Press, Inc. (1980), followed by oligo dT cellulose chromatography to yield poly A+ RNA (3&#39;-polyadenylated eukaryotic RNA containing most mRNA sequences that can be translated into polypeptides). To obtain approximately 100 ug of poly A+ RNA, approximately 3×10 8  cells of transfectant 23.411 or tumor cell line HT-29 (ATCC HTB 38) are harvested from roller bottles after late logarithmic growth. Cells are lysed by homogenization in an ice-cold solution of 140 mM NaCl, 1.5 mM MgCl 2 , 10 mM Tris-Hcl, pH 8.0, 0.5% NP40, 4 mM dithiothreitol and 20 units of placental ribonuclease inhibitor/ml. Sodium deoxycholate was then added to 0.2%. Cytoplasm and nuclei are separated by centrifugation of the homogenate at 12,000×g for 20 minutes. The cytoplasmic fraction is mixed with an equal volume of 0.2 M Tris-Hcl, pH 7.8, 25 mM EDTA, 0.3 M NaCl, 2% sodium dodecyl sulfate and 400 μg/ml of proteinase K, incubated for 1 hour at 37° C., the extracted once with an equal volume of phenol/chloroform (1:1/v:v) solution. Nucleic acids are obtained by ethanol precipitation of the separated aqueous phase. Total RNA is enriched by passage in 0.5 M NaCl, 10 mM Tris-HCl, pH 7.8, 0.1% sarcosyl through an oligo dT(12-18) cellulose column. After washing, bound RNA is eluted in the same solution without sodium chloride. 
     Example 3b 
     Reverse Transcription of mRNA 
     Ten micrograms of 23.411 or HT 29 poly A+ RNA are primed for reverse transcription with oligo dT(12-18) and pdN 6  primers. One hundred microliter reaction was performed for 4 hours at 42° C. with 200 units AMV reverse transcriptase (Life Science, Inc. St. Petersburg, Fla., U.S.A.). The RNA component of the cDNA/mRNA hybrids is replaced with the second complementary strand by treatment with RNase H, E. coli DNA polymerase I and E. coli DNA ligase at 12° C. and 22° C. for 1.5 hours each. Molecular ends are polished by treatment with T4 DNA polymerase. cDNA is phenol/chloroform extracted and purified over a &#34;SEPHADEX G-50&#34; spun column prepared in 10 mM Tris-HCl, pH 7.8, 1 mM EDTA (TE). 
     Example 3c 
     Cloning of cDNA for CEA-(g) 
     Synthetic DNA linkers ##STR10## are attached to the ends of cDNA by blunt and ligation with excess T4 DNA ligase. Excess linkers are removed by chromatography through &#34;SEPHADEX G-50&#34; (medium) in TE, and by fractionation on 0.8% low melting agarose gel. Based on Northern blot analysis of poly A+ RNA of the 23.411 and HT-29 cell lines, the size of the CEA-related mRNA is estimated at 1.7 kb. Therefore, cDNA fragments between 1 and 2 kb are recovered from gel slices and fragments are ethanol precipitated. After resuspension of cDNA in TE, EcoRI-cleaved lambda gt10 arms are added to cDNA at an estimated molar ratio of 1:1. Ligation proceeds at 7° C. for 2 days in the presence of T4 DNA ligase. Aliquots of the ligation reaction are added to commercially-obtained packaging mix (Stratagene, San Diego, Calif., U.S.A.). Pharge particles are obtained after in vitro packaging and infection of E. coli host NM514. 
     Example 3d 
     Screening of Recombinant Library 
     Five hundred thousand to one million packaged lambda particles are plated on lawns of E. coli NM514 and replicate patterns are lifted onto nitrocellulose sheets as described by W. D. Benton and R. W. Davis, Science, 196, 180-182, (1977). Positive phage are selected by hybridization with  32  P-labeled LV7 cDNA insert probe that contained a domain repeated amoung various CEA family members. By this selection method, positive phage are obtained after multiple rounds of screening. Phage from individual plaques are amplified and titered, and these are used to prepare small quantities of recombinant phage DNA. 
     Example 3e 
     DNA Manipulation 
     Phage DNA is prepared according to T. Maniatis, E. Fritsch and J. Sambrook, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor, (1982). DNA segments are isolated from low melting agarose gels and inserted for subcloning into Bluescript plasmid vectors (Stratagene, San Diego, Calif., U.S.A.). DNA sequencing is performed by the dideoxy termination method of F. Sanger, S. Nicklen and A. Coulson, Proc. Natl. Acad. Sci., U.S.A., 74, 5463-5467, (1977). The nucleotide and translated sequence for a cDNA coding for CEA-(g) is given hereinabove (TM-4 (CEA-(g)). 
     EXAMPLE 4 
     Screening of KG-1 cDNA Library with  32  P-labelled CEA Probe, LV7 (CEA-(A)) 
     A segment of cDNA coding for a portion of carcinoembryonic antigen [LV7 or CEA-(a)] was radiolabelled by random priming and used to detect homologous sequences on filter replicas of a commercial cDNA library prepared from KG-1 cells in bacteriophage vector λgt11 (Clontech Laboratories, Inc., Palo Alto, Calif., U.S.A.). Hybridizations were performed at 68° C. in 2×SSSPE (1×SSPE--0.15 M NaCl, 0.01 M sodium phosphate and 1 mM EDTA, pH 7), 5×Denhardt&#39;s solution and 100 μg of denatured salmon sperm DNA per ml, and post-hybridization washes were in 0.2×SSC, 0.25% sodium dodecyl sulfate. 
     Positive phage were picked, rescreened to homogeneity, and amplified for production of DNA. cDNA inserts were excised from phage DNA with EcoRI enconuclease and subcloned into the EcoRI site of the plasmid vector pBluescript KS. DNA sequencing on double-stranded DNA was by the method of Sanger et al, supra. The sequences of two different inserts from the KG-1 cDNA library are shown below: ##STR11## which has been designated SEQ ID No:8 and SEQ ID No:16 for the translated polypeptide. ##STR12## which has been designated SEQ ID No:9 and SEQ ID No:17 for the translated polypeptide. 
     It will be appreciated that the instant specification and claims are set forth by way of illustration and not limitation and that various modifications and changes may be made without departing from the spirit and scope of the present invention. 
     
         __________________________________________________________________________SEQUENCE LISTING__________________________________________________________________________(1)  GENERAL INFORMATION:(i)  APPLICANT:         BARNETT, THOMAS R         ELTING, JAMES J         KAMARCK, MICHAEL E         KRETSCHMER, A W(ii) TITLE OF INVENTION: CDNAS CODING FOR MEMBERS OF THECARCINOEMBRYONIC ANTIGEN FAMILY(iii)NUMBER OF SEQUENCES: 1(iv) CORRESPONDENCE ADDRESS:(A)     ADDRESSEE: SPRUNG HORN KRAMER &amp; WOODS(B)     STREET: 1140 AVENUE OF THE AMERICAS(C)     CITY: NEW YORK(D)     STATE: NEW YORK(E)     COUNTRY: U.S.A.(F)     ZIP: 10036(v)  COMPUTER READABLE FORM:(A)     MEDIUM TYPE: Floppy disk(B)     COMPUTER: IBM PC compatible(C)     OPERATING SYSTEM: PC-DOS/MS-DOS(D)     SOFTWARE: PatentIn Release #1.0, Version #1.25(vi) CURRENT APPLICATION DATA:(A)     APPLICATION NUMBER: US 07/760,031(B)     FILING DATE: 13-NOV-1991(C)     CLASSIFICATION: UNASSIGNED(viii)ATTORNEY/AGENT INFORMATION:(A)     NAME: VASTA JR, VINCENT J(B)     REGISTRATION NUMBER: 26,655(C)     REFERENCE/DOCKET NUMBER: MDI 242.5-VJV(ix) TELECOMMUNICATION INFORMATION:(A)     TELEPHONE: (212) 391-0520(B)     TELEFAX: (212) 382-0949(C)     TELEX: 423092 NYP UI(2)  INFORMATION FOR SEQ ID NO:1:(i)  SEQUENCE CHARACTERISTICS:(A)     LENGTH: 859 base pairs(B)     TYPE: nucleic acid(C)     STRANDEDNESS: double(D)     TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(iii)HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(vi) ORIGINAL SOURCE:(A)     ORGANISM: HOMO SAPIENS(vii)IMMEDIATE SOURCE:(B)     CLONE: CEA-(a) [LV7](xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:GGGGTTTACA     CAACCACCAC               CCCATCAAAC                         CCTTCATCAC                                   CAGCAACAAC                                             TCCAACCCCG                                                       60TGGAGGATGA     GGATGCTGTA               GCCTTAACCT                         GTGAACCTGA                                   GATTCAGAAC                                             ACAACCTACC                                                       120TGTGGTGGGT     AAATAATCAG               AGCCTCDCCG                         GTCAGTCCCA                                   GGCTGCAGCT                                             GTCCAATGAC                                                       180AACAGGACCC     TCACTCTACT               CAGTGTCACA                         AGGAATGATG                                   TAGGACCCTA                                             TGCGTGTGGA                                                       240ATCCAGAACG     AATTAAGTGT               TGACCACAGC                         GACCCAGTCA                                   CCCAGCGATT                                             CCTCTATGGC                                                       300CCAGACGACC     CCACCATTTC               CCCCTCATAC                         ACCTATTACC                                   GTCCAGGGGT                                             GGAACCTCAG                                                       360CCTCTCTGCC     ATGCAGCCTC               TAACCCACCT                         GCACAGTATT                                   CTTGGCTGAT                                             TGATGGGACC                                                       420GTCCAGCAAC     ACACACAAGA               GCTCTTTATC                         TCCAACATCA                                   CTGAGAAGAA                                             CAGCGGACTC                                                       480TATACCTGCC     AGGCCAATAA               CTCAGCCAGT                         GGCACAGCAG                                   GACTACAGTC                                             AAGACAATCA                                                       540CAGTCTCTGC     GGATGCCCAG               CCCTCCATCT                         CCAGCAACAA                                   CTCCAAACCC                                             GTGGAGGACA                                                       600AGGATCGCTG     TGGCCTTCAC               TGTGAACCTG                         AGGCTCAGAA                                   CACAACCTAC                                             CTGTGGTGGG                                                       660TAAATGGTCA     GAGCCTCCCA               GTCAGTCCCA                         GGCTGCAGCT                                   GTCCAATGGC                                             AACAGGACCC                                                       720TCACTCTGTT     CAATGTCACA               AGAAATGACG                         CAAGAGCCTA                                   TGTATGTGGA                                             ATCCAGAACT                                                       780CAGTGAGTGC     AAACCGCAGT               GACCCAGTCA                         CCCTGGATGT                                   CCTCTATGGG                                             CCGGACACCC                                                       840CCATCATTTC     CCCCCCCCC                                         859__________________________________________________________________________ 
    
     
         __________________________________________________________________________SEQUENCE LISTING__________________________________________________________________________(1)  GENERAL INFORMATION:(i)  APPLICANT:         BARNETT, THOMAS R         ELTING, JAMES J         KAMARCK, MICHAEL E         KRETSCHMER, A W(ii) TITLE OF INVENTION: CDNAS CODING FOR MEMBERS OF THECARCINOEMBRYONIC ANTIGEN FAMILY(iii)NUMBER OF SEQUENCES: 1(iv) CORRESPONDENCE ADDRESS:(A)     ADDRESSEE: SPRUNG HORN KRAMER &amp; WOODS(B)     STREET: 1140 AVENUE OF THE AMERICAS(C)     CITY: NEW YORK(D)     STATE: NEW YORK(E)     COUNTRY: U.S.A.(F)     ZIP: 10036(v)  COMPUTER READABLE FORM:(A)     MEDIUM TYPE: Floppy disk(B)     COMPUTER: IBM PC compatible(C)     OPERATING SYSTEM: PC-DOS/MS-DOS(D)     SOFTWARE: PatentIn Release #1.0, Version #1.25(vi) CURRENT APPLICATION DATA:(A)     APPLICATION NUMBER: US 07/760,031(B)     FILING DATE: 13-NOV-1991(C)     CLASSIFICATION: UNASSIGNED(viii)ATTORNEY/AGENT INFORMATION:(A)     NAME: VASTA JR, VINCENT J(B)     REGISTRATION NUMBER: 26,655(C)     REFERENCE/DOCKET NUMBER: MDI 242.5-VJV(ix) TELECOMMUNICATION INFORMATION:(A)     TELEPHONE: (212) 391-0520(B)     TELEFAX: (212) 382-0949(C)     TELEX: 423092 NYP UI(2)  INFORMATION FOR SEQ ID NO:2:(i)  SEQUENCE CHARACTERISTICS:(A)     LENGTH: 2839 base pairs(B)     TYPE: nucleic acid(C)     STRANDEDNESS: double(D)     TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(iii)HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(vi) ORIGINAL SOURCE:(A)     ORGANISM: HOMO SAPIENS(vii)IMMEDIATE SOURCE:(B)     CLONE: CEA-(b) [1LV7](xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:CACCATGGAG     TCTCCCTCGG               CCCCTCCCCA                         CAGATGGTGC                                   ATCCCCTGGC                                             AGAGGCTCCT                                                       60GCTCACAGCC     TCACTTCTAA               CCTTCTGGAA                         CCCGCCCACC                                   ACTGCCAAGC                                             TCACTATTGA                                                       120ATCCACGCCG     TTCAATGTCG               CAGAGGGGAA                         GGAGGTGCTT                                   CTACTTGTCC                                             ACAATCTGCC                                                       180CCAGCATCTT     TTTGGCTACA               GCTGGTACAA                         AGGTGAAAGA                                   GTGGATGGCA                                             ACCGTCAAAT                                                       240TATAGGATAT     GTAATAGGAA               CTCAACAAGC                         TACCCCAGGG                                   CCCGCATACA                                             GTGGTCGAGA                                                       300GATAATATAC     CCCAATGCAT               CCCTGCTGAT                         CCAGAACATC                                   ATCCAGAATG                                             ACACAGGATT                                                       360CTACACCCTA     CACGTCATAA               AGTCAGATCT                         TGTGAATGAA                                   GAAGCAACTG                                             GCCAGTTCCG                                                       420GGTATACCCG     GAGCTGCCCA               AGCCCTCCAT                         CTCCAGCAAC                                   AACTCCAAAC                                             CCGTGGAGGA                                                       480CAAGGATGCT     GTGGCCTTCA               CCTGTGAACC                         TGAGACTCAG                                   GACGCAACCT                                             ACCTGTGGTG                                                       540GGTAAACAAT     CAGAGCCTCC               CGGTCAGTCC                         CAGGCTGCAG                                   CTGTCCAATG                                             GCAACAGGAC                                                       600CCTCACTCTA     TTCAATGTCA               CAAGAAATGA                         CACAGCAAGC                                   TACAAATGTG                                             AAACCCAGAA                                                       660CCCAGTGAGT     GCCAGGCGCA               GTGATTCAGT                         CATCCTGAAT                                   GTCCTCTATG                                             GCCCGGATGC                                                       720CCCCACCATT     TCCCCTCTAA               ACACATCTTA                         CAGATCAGGG                                   GAAAATCTGA                                             ACCTCTCCTG                                                       780CCACGCAGCC     TCTAACCCAC               CTGCACAGTA                         CTCTTGGTTT                                   GTCAATGGGA                                             CTTTCCAGCA                                                       840ATCCACCCAA     GAGCTCTTTA               TCCCCAACAT                         CACTGTGAAT                                   AATAGTGGAT                                             CCTATACGTG                                                       900CCAAGCCCAT     AACTCAGACA               CTGGCCTCAA                         TAGGACCACA                                   GTCACGACGA                                             TCACAGTCTA                                                       960TGCAGAGCCA     CCCAAACCCT               TCATCACCAG                         CAACAACTCC                                   AACCCCGTGG                                             AGGATGAGGA                                                       1020TGCTGTAGCC     TTAACCTGTG               AACCTGAGAT                         TCAGAACACA                                   ACCTACCTGT                                             GGTGGGTAAA                                                       1080TAATCAGAGC     CTCCCGGTCA               GTCCCAGGCT                         GCAGCTGTCC                                   AATGACAACA                                             GGACCCTCAC                                                       1140TCTACTCAGT     GTCACAAGGA               ATGATGTAGG                         ACCCTATGAG                                   TGTGGAATCC                                             AGAACGAATT                                                       1200AAGTGTTGAC     CACAGCGACC               CAGTCATCCT                         GAATGTCCTC                                   TATGGCCCAG                                             ACGACCCCAC                                                       1260CATTTCCCCC     TCATACACCT               ATTACCGTCC                         AGGGGTGAAC                                   CTCAGCCTCT                                             CCTGCCATGC                                                       1320AGCCTCTAAC     CCACCTGCAC               AGTATTCTTG                         GCTGATTGAT                                   GGGAACATCC                                             AGCAACACAC                                                       1380ACAAGAGCTC     TTTATCTCCA               ACATCACTGA                         GAAGAACAGC                                   GGACTCTATA                                             CCTGCCAGGC                                                       1440CAATAACTCA     GCCAGTGGCC               ACAGCAGGAC                         TACAGTCAAG                                   ACAATCACAG                                             TCTCTGCGGA                                                       1500GCTGCCCAAG     CCCTCCATCT               CCAGCAACAA                         CTCCAAACCC                                   GTGGAGGACA                                             AGGATGCTGT                                                       1560GGCCTTCACC     TGTGAACCTG               AGGCTCAGAA                         CACAACCTAC                                   CTGTGGTGGG                                             TAAATGGTCA                                                       1620GAGCCTCCCA     GTCAGTCCCA               GGCTGCAGCT                         GTCCAATGGC                                   AACAGGACCC                                             TCACTCTATT                                                       1680CAATGTCACA     AGAAATGACG               CAAGAGCCTA                         TGTATGTGGA                                   ATCCAGAACT                                             CAGTGAGTGC                                                       1740AAACCGCAGT     GACCCAGTCA               CCCTGGATGT                         CCTCTATGGG                                   CCGGACACCC                                             CCATCATTTC                                                       1800CCCCCCAGAC     TCGTCTTACC               TTTCGGGAGC                         GAACCTCAAC                                   CTCTCCTGCC                                             ACTCGGCCTC                                                       1860TAACCCATCC     CCGCAGTATT               CTTGGCGTAT                         CAATGGGATA                                   CCGCAGCAAC                                             ACACACAAGT                                                       1920TCTCTTTATC     GCCAAAATCA               CGCCAAATAA                         TAACGGGACC                                   TATGCCTGTT                                             TTGTCTCTAA                                                       1980CTTGGCTACT     GGCCGCAATA               ATTCCATAGT                         CAAGAGCATC                                   ACAGTCTCTG                                             CATCTGGAAC                                                       2040TTCTCCTGGT     CTCTCAGCTG               GGGCCACTGT                         CGGCATCATG                                   ATTGGAGTGC                                             TGGTTGGGGT                                                       2100TGCTCTGATA     TAGCAGCCCT               GGTGTAGTTT                         CTTCATTTCA                                   GGAAGACTGA                                             CAGTTGTTTT                                                       2160GCTTCTTCCT     TAAAGCATTT               GCAACAGCTA                         CAGTCTAAAA                                   TTGCTTCTTT                                             ACCAAGGATA                                                       2220TTTACAGAAA     AGACTCTGAC               CAGAGATCGA                         GACCATCCTA                                   GCCAACATCG                                             TGAAACCCCA                                                       2280TCTCTACTAA     AAATACAAAA               ATGAGCTGGG                         CTTGGTGGCG                                   CGCACCTGTA                                             GTCCCAGTTA                                                       2340CTCGGGAGGC     TGAGGCAGGA               GAATCGCTTG                         AACCCGGGAG                                   GTGGAGATTG                                             CAGTGAGCCC                                                       2400AGATCGCACC     ACTGCACTCC               AGTCTGGCAA                         CAGAGCAAGA                                   CTCCATCTCA                                             AAAAGAAAAG                                                       2460AAAAGAAGAC     TCTGACCTGT               ACTCTTGAAT                         ACAAGTTTCT                                   GATACCACTG                                             CACTGTCTGA                                                       2520GAATTTCCAA     AACTTTAATG               AACTAACTGA                         CAGCTTCATG                                   AAACTGTCCA                                             CCAAGATCAA                                                       2580GCAGAGAAAA     TAATTAATTT               CATGGGACTA                         AATGAACTAA                                   TGAGGATAAT                                             ATTTTCATAA                                                       2640TTTTTTATTT     GAAATTTTGC               TGATTCTTTA                         AATGTCTTGT                                   TTCCCAGATT                                             TCAGGAAACT                                                       2700TTTTTTCTTT     TAAGCTATCC               ACAGCTTACA                         GCAATTTGAT                                   AAAATATACT                                             TTTGTGAACA                                                       2760AAAATTGAGA     CATTTACATT               TTCTCCCTAT                         GTGGTCGCTC                                   CAGACTTGGG                                             AAACTATTCA                                                       2820TGAATATTTA     TATTGTATG                                         2839__________________________________________________________________________ 
    
     
         __________________________________________________________________________SEQUENCE LISTING__________________________________________________________________________(1)  GENERAL INFORMATION:(i)  APPLICANT:         BARNETT, THOMAS R         ELTING, JAMES J         KAMARCK, MICHAEL E         KRETSCHMER, A W(ii) TITLE OF INVENTION: CDNAS CODING FOR MEMBERS OF THECARCINOEMBRYONIC ANTIGEN FAMILY(iii)NUMBER OF SEQUENCES: 1(iv) CORRESPONDENCE ADDRESS:(A)     ADDRESSEE: SPRUNG HORN KRAMER &amp; WOODS(B)     STREET: 1140 AVENUE OF THE AMERICAS(C)     CITY: NEW YORK(D)     STATE: NEW YORK(E)     COUNTRY: U.S.A.(F)     ZIP: 10036(v)  COMPUTER READABLE FORM:(A)     MEDIUM TYPE: Floppy disk(B)     COMPUTER: IBM PC compatible(C)     OPERATING SYSTEM: PC-DOS/MS-DOS(D)     SOFTWARE: PatentIn Release #1.0, Version #1.25(vi) CURRENT APPLICATION DATA:(A)     APPLICATION NUMBER: US 07/760,031(B)     FILING DATE: 13-NOV-1991(C)     CLASSIFICATION: UNASSIGNED(viii)ATTORNEY/AGENT INFORMATION:(A)     NAME: VASTA JR, VINCENT J(B)     REGISTRATION NUMBER: 26,655(C)     REFERENCE/DOCKET NUMBER: MDI 242.5-VJV(ix) TELECOMMUNICATION INFORMATION:(A)     TELEPHONE: (212) 391-0520(B)     TELEFAX: (212) 382-0949(C)     TELEX: 423092 NYP UI(2)  INFORMATION FOR SEQ ID NO:3:(i)  SEQUENCE CHARACTERISTICS:(A)     LENGTH: 3461 base pairs(B)     TYPE: nucleic acid(C)     STRANDEDNESS: double(D)     TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(iii)HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(vi) ORIGINAL SOURCE:(A)     ORGANISM: HOMO SAPIENS(vii)IMMEDIATE SOURCE:(B)     CLONE: CEA-(c) [16-19](xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:CAGCCGTGCT     CGAAGCGTTC               CTGGAGCCCA                         AGCTCTCCTC                                   CACAGGTGAA                                             GACAGGGCCA                                                       60GCAGGAGACA     CCATGGGGCA               CCTCTCAGCC                         CCACTTCACA                                   GAGTGCGTGT                                             ACCCTGGCAG                                                       120GGGCTTCTGC     TCACAGCCTC               ACTTCTAACC                         TTCTGGAACC                                   CGCCCACCAC                                             TGCCCAGCTC                                                       180ACTACTGAAT     CCATGCCATT               CAATGTTGCA                         GAGGGGAAGG                                   AGGTTCTTCT                                             CCTTGTCCAC                                                       240AATCTGCCCC     AGCAACTTTT               TGGCTACAGC                         TGGTACAAAG                                   GGGAAAGAGT                                             GGATGGCAAC                                                       300CGTCAAATTG     TAGGATATGC               AATAGGAACT                         CAACAAGCTA                                   CCCCAGGGCC                                             CGCAAACAGC                                                       360GGTCGAGAGA     CAATATACCC               CAATGCATCC                         CTGCTGATCC                                   AGAACGTCAC                                             CCAGAATGAC                                                       420ACAGGATTCT     ACACCCTACA               AGTCATAAAG                         TCAGATCTTG                                   TGAATGAAGA                                             AGCAACTGGA                                                       480CAGTTCCATG     TATACCCGGA               GCTGCCCAAG                         CCCTCCATCT                                   CCAGCAACAA                                             CTCCAACCCT                                                       540GTGGAGGACA     AGGATGCTGT               GGCCTTCACC                         TATGAACCTG                                   AGACTCAGGA                                             CACAACCTAC                                                       600CTGTGGTGGA     TAAACAATCA               GAGCCTCCCG                         GTCAGTCCCA                                   GGCTGCAGCT                                             GTCCAATGGC                                                       660AACAGGACCC     TCACTCTACT               CAGTGTCACA                         AGGAATGACA                                   CAGGACCCTA                                             TGAGTGTGAA                                                       720ATACAGAACC     CAGTGAGTGC               GAACCGCAGT                         GACCCAGTCA                                   CCTTGAATGT                                             CACCTATGGC                                                       780CCGGACACCC     CCACCATTTC               CCCTTCAGAC                         ACCTATTACC                                   GTCCAGGGGC                                             AAACCTCAGC                                                       840CTCTCCTGCT     ATGCAGCCTC               TAACCCACCT                         GCACAGTACT                                   CCTGGCTTAT                                             CAATGGAACA                                                       900TTCCAGCAAA     GCACACAAGA               GCTCTTTATC                         CCTAACATCA                                   CTGTGAATAA                                             TAGTGGATCC                                                       960TATACCTGCC     ACGCCAATAA               CTCAGTCACT                         GGCTGCAACA                                   GGACCACAGT                                             CAAGACGATC                                                       1020ATAGTCACTG     AGCTAAGTCC               AGTAGTAGCA                         AAGCCCCAAA                                   TCAAAGCCAG                                             CAAGACCACA                                                       1080GTCACAGGAG     ATAAGGACTC               TGTGAACCTG                         ACCTGCTCCA                                   CAAATGACAC                                             TGGAATCTCC                                                       1140ATCCGTTGGT     TCTTCAAAAA               CCAGAGTCTC                         CCGTCCTCGG                                   AGAGGATGAA                                             GCTGTCCCAG                                                       1200GGCAACACCA     CCCTCAGCAT               AAACCCTGTC                         AAGAGGGAGG                                   ATGCTGGGAC                                             GTATTGGTGT                                                       1260GAGGTCTTCA     ACCCAATCAG               TAAGAACCAA                         AGCGACCCCA                                   TCATGCTGAA                                             CGTAAACTAT                                                       1320AATGCTCTAC     CACAAGAAAA               TGGCCTCTCA                         CCTGGGGCCA                                   TTGCTGGCAT                                             TGTGATTGGA                                                       1380GTAGTGGCCC     TGGTTGCTCT               GATAGCAGTA                         GCCCTGGCAT                                   GTTTTCTGCA                                             TTTCGGGAAG                                                       1440ACCGGCAGGG     CAAGCGACCA               GCGTGATCTC                         ACAGAGCACA                                   AACCCTCAGT                                             CTCCAACCAC                                                       1500ACTCAGGACC     ACTCCAATGA               CCCACCTAAC                         AAGATGAATG                                   AAGTTACTTA                                             TTCTACCCTG                                                       1560AACTTTGAAG     CCCAGCAACC               CACACAACCA                         ACTTCAGCCT                                   CCCCATCCCT                                             AACAGCCACA                                                       1620GAAATAATTT     ATTCAGAAGT               AAAAAAGCAG                         TAATGAAACC                                   TGTCCTGCTC                                             ACTGCAGTGC                                                       1680TGATGTATTT     CAAGTCTCTC               ACCCTCATCA                         CTAGGAGATT                                   CCTTTCCCCT                                             GTAGGGTAGA                                                       1740GGGGTGGGGA     CAGAAACAAC               TTTCTCCTAC                         TCTTCCTTCC                                   TAATAGGCAT                                             CTCCAGGCTG                                                       1800CCTGGTCACT     GCCCCTCTCT               CAGTGTCAAT                         AGATGAAAGT                                   ACATTGGGAG                                             TCTGTAGGAA                                                       1860ACCCAACCTT     CTTGTCATTG               AAATTTGGCA                         AAGCTGACTT                                   TGGGAAAGAG                                             GGACCAGAAC                                                       1920TTCCCCTCCC     TTCCCCTTTT               CCCAACCTGG                         ACTTGTTTTA                                   AACTTGCCTG                                             TTCAGAGCAC                                                       1980TCATTCCTTC     CCACCCCCAG               TCCTGTCCTA                         TCACTCTAAT                                   TCGGATTTGC                                             CATAGCCTTG                                                       2040AGGTTATGTC     CTTTTCCATT               AAGTACATGT                         GCCAGGAAAC                                   AGCGAGAGAG                                             AGAAAGTAAA                                                       2100CGGCAGTAAT     GCTTCTCCTA               TTTCTCCAAA                         GCCTTGTGTG                                   AACTAGCAAA                                             GAGAAGAAAA                                                       2160TCAAATATAT     AACCAATAGT               GAAATGCCAC                         AGGTTTGTCC                                   ACTGTCAGGG                                             TTGTCTACCT                                                       2220GTAGGATCAG     GGTCTAAGCA               CCTTGGTGCT                         TAGCTAGAAT                                   ACCACCTAAT                                             CCTTCTGGCA                                                       2280AGCCTGTCTT     CAGAGAACCC               ACTAGAAGCA                         ACTAGGAAAA                                   ATCACTTGCC                                             AAAATCCAAG                                                       2340GCAATTCCTG     ATGGAAAATG               CAAAAGCACA                         TATATGTTTT                                   AATATCTTTA                                             TGGGCTCTGT                                                       2400TCAAGGCAGT     GCTGAGAGGG               AGGGGTTATA                         GCTTCAGGAG                                   GGAACCAGCT                                             TCTGATAAAC                                                       2460ACAATCTGCT     AGGAACTTGG               GAAAGGAATC                         AGAGAGCTGC                                   CCTTCAGCGA                                             TTATTTAAAT                                                       2520TGTTAAAGAA     TACACAATTT               GGGGTATTGG                         GATTTTTCTC                                   CTTTTCTCTG                                             AGACATTCCA                                                       2580CCATTTTAAT     TTTTGTAACT               GCTTATTTAT                         GTGAAAAGGG                                   TTATTTTTAC                                             TTAGCTTAGC                                                       2640TATGTCAGCC     AATCCGATTG               CCTTAGGTGA                         AAGAAACCAC                                   CGAAATCCCT                                             CAGGTCCCTT                                                       2700GGTCAGGAGC     CTCTCAAGAT               TTTTTTTGTC                         AGAGGCTCCA                                   AATAGAAAAT                                             AAGAAAAGGT                                                       2760TTTCTTCATT     CATGGCTAGA               GCTAGATTTA                         ACTCAGTTTC                                   TAGGCACCTC                                             AGACCAATCA                                                       2820TCAACTACCA     TTCTATTCCA               TGTTTGCACC                         TGTGCATTTT                                   CTGTTTGCCC                                             CCATTCACTT                                                       2880TGTCAGGAAA     CCTTGGCCTC               TGCTAAGGTG                         TATTTGGTCC                                   TTGAGAAGTG                                             GGAGCACCCT                                                       2940ACAGGGACAC     TATCACTCAT               GCTGGTGGCA                         TTGTTTACAG                                   CTAGAAAGCT                                             GCACTGGTGC                                                       3000TAATGCCCCT     TGGGAAATGG               GGCTGTGAGG                         AGGAGGATTA                                   TAACTTAGGC                                             CTAGCCTCTT                                                       3060TTAACAGCCT     CTGAAATTTA               TCTTTTCTTC                         TATGGGGTCT                                   ATAAATGTAT                                             CTTATAATAA                                                       3120AAAGGAAGGA     CAGGAGGAAG               ACAGGCAAAT                         GTACTTCTCA                                   CCCAGTCTTC                                             TACACAGATG                                                       3180GAATCTCTTT     GGGGCTAAGA               GAAAGGTTTT                         ATTCTATATT                                   GCTTACCTGA                                             TCTCATGTTA                                                       3240GGCCTAAGAG     GCTTTCTCCA               GGAGGATTAG                         CTTGGAGTTC                                   TCTATACTCA                                             GGTACCTCTT                                                       3300TCAGGGTTTT     CTAACCCTGA               CACGGACTGT                         GCATACTTTC                                   CCTCATCCAT                                             GCTGTGCTGT                                                       3360GTTATTTAAT     TTTTCCTGGC               TAAGATCATG                         TCTGAATTAT                                   GTATGAAAAT                                             TATTCTATGT                                                       3420TTTTATAATA     AAAATAATAT               ATCAGACATC                         GAAAAAAAAA                                   A                   3461__________________________________________________________________________ 
    
     
         __________________________________________________________________________SEQUENCE LISTING__________________________________________________________________________(1)  GENERAL INFORMATION:(i)  APPLICANT:         BARNETT, THOMAS R         ELTING, JAMES J         KAMARCK, MICHAEL E         KRETSCHMER, A W(ii) TITLE OF INVENTION: CDNAS CODING FOR MEMBERS OF THECARCINOEMBRYONIC ANTIGEN FAMILY(iii)NUMBER OF SEQUENCES: 1(iv) CORRESPONDENCE ADDRESS:(A)     ADDRESSEE: SPRUNG HORN KRAMER &amp; WOODS(B)     STREET: 1140 AVENUE OF THE AMERICAS(C)     CITY: NEW YORK(D)     STATE: NEW YORK(E)     COUNTRY: U.S.A.(F)     ZIP: 10036(v)  COMPUTER READABLE FORM:(A)     MEDIUM TYPE: Floppy disk(B)     COMPUTER: IBM PC compatible(C)     OPERATING SYSTEM: PC-DOS/MS-DOS(D)     SOFTWARE: PatentIn Release #1.0, Version #1.25(vi) CURRENT APPLICATION DATA:(A)     APPLICATION NUMBER: US 07/760,031(B)     FILING DATE: 13-NOV-1991(C)     CLASSIFICATION: UNASSIGNED(viii)ATTORNEY/AGENT INFORMATION:(A)     NAME: VASTA JR, VINCENT J(B)     REGISTRATION NUMBER: 26,655(C)     REFERENCE/DOCKET NUMBER: MDI 242.5-VJV(ix) TELECOMMUNICATION INFORMATION:(A)     TELEPHONE: (212) 391-0520(B)     TELEFAX: (212) 382-0949(C)     TELEX: 423092 NYP UI(2)  INFORMATION FOR SEQ ID NO:4:(i)  SEQUENCE CHARACTERISTICS:(A)     LENGTH: 1964 base pairs(B)     TYPE: nucleic acid(C)     STRANDEDNESS: double(D)     TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(iii)HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(vi) ORIGINAL SOURCE:(A)     ORGANISM: HOMO SAPIENS(vii)IMMEDIATE SOURCE:(B)     CLONE: CEA-(d) [BT-20](xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:CCGGGGGACA     CGCAGGGCCA               ACAGTCACAG                         CAGCCCTGAC                                   CAGAGCATTC                                             CTGGAGCTCA                                                       60AGCTCTCTAC     AAAGAGGTGG               ACAGAGAAGA                         CAGCAGAGAC                                   CATGGGACCC                                             CCCTCAGCCC                                                       120CTCCCTGCAG     ATTGCATGTC               CCCTGGAAGG                         AGGTCCTGCT                                   CACAGCCTCA                                             CTTCTAACCT                                                       180TCTGGAACCC     ACCCACCACT               GCCAAGCTCA                         CTATTGAATC                                   CACGCCATTC                                             AATGTCGCAG                                                       240AGGGGAAGGA     GGTTCTTCTA               CTCGCCCACA                         ACCTGCCCCA                                   GAATCGTATT                                             GGTTACAGCT                                                       300GGTACAAAGG     CGAAAGAGTG               GATGGCAACA                         GTCTAATTGT                                   AGGATATGTA                                             ATAGGAACTC                                                       360AACAAGCTAC     CCCAGGGCCC               GCATACAGTG                         GTCGAGAGAC                                   AATATACCCC                                             AATGCATCCC                                                       420TGCTGATCCA     GAACGTCACC               CAGAATGACA                         CAGGATTCTA                                   CACCCTACAA                                             GTCATAAAGT                                                       480CAGATCTTGT     GAATGAAGAA               GCAACCGGAC                         AGTTCCATGT                                   ATACCCGGAG                                             CTGCCCAAGC                                                       540CCTCCATCTC     CAGCAACAAC               TCCAACCCCG                         TGGAGGACAA                                   GGATGCTGTG                                             GCCTTCACCT                                                       600GTGAACCTGA     GGTTCAGAAC               ACAACCTACC                         TGTGGTGGGT                                   AAATGGTCAG                                             AGCCTCCCGG                                                       660TCAGTCCCAG     GCTGCAGCTG               TCCAATGGCA                         ACAGGACCCT                                   CACTCTACTC                                             AGCGTCAAAA                                                       720GGAACGATGC     AGGATCGTAT               GAATGTGAAA                         TACAGAACCC                                   AGCGAGTGCC                                             AACCGCAGTG                                                       780ACCCAGTCAC     CCTGAATGTC               CTCTATGGCC                         CAGATGGCCC                                   CACCATTTCC                                             CCCTCAAAGG                                                       840CCAATTACCG     TCCAGGGGAA               AATCTGAACC                         TCTCCTGCCA                                   CGCAGCCTCT                                             AACCCACCTG                                                       900CACAGTACTC     TTGGTTTATC               AATGGGACGT                         TCCAGCAATC                                   CACACAAGAG                                             CTCTTTATCC                                                       960CCAACATCAC     TGTGAATAAT               AGCGGATCCT                         ATATGTGCCA                                   AGCCCATAAC                                             TCAGCCACTG                                                       1020GCCTCAATAG     GACCACAGTC               ACGATGATCA                         CAGTCTCTGG                                   AAGTGCTCCT                                             GTCCTCTCAG                                                       1080CTGTGGCCAC     CGTCGGCATC               ACGATTGGAG                         TGCTGGCCAG                                   GGTGGCTCTG                                             ATATAGCAGC                                                       1140CCTGGTGTAT     TTTCGATATT               TCAGGAAGAC                         TGGCAGATTG                                   GACCAGACCC                                             TGAATTCTTC                                                       1200TAGCTCCTCC     AATCCCATTT               TATCCCATGG                         AACCACTAAA                                   AACAAGGTCT                                             GCTCTGCTCC                                                       1260TGAAGCCCTA     TATGCTGGAG               ATGGACAACT                         CAATGAAAAT                                   TTAAAGGGAA                                             AACCCTCAGG                                                       1320CCTGAGGTGT     GTGCCACTCA               GAGACTTCAC                         CTAACTAGAG                                   ACAGGCAAAC                                             TGCNNNCCAN                                                       1380NCCTCTTTCG     CTTGGCAGGN               TGATGCTGTC                         ATTAGTATTT                                   CACAAGAAGT                                             AGCTTCAGAG                                                       1440GGTAACTTAA     CAGAGTATCA               GATCTATCTT                         GTCAATCCCA                                   ACGTTTTACA                                             TAAAATAAGA                                                       1500GATCCTTTAG     TGCACCCAGT               GACTGACATT                         AGCAGCATCT                                   TTAACACAGC                                             CGTGTGTTCA                                                       1560AATGTACAGT     GGTCCTTTTC               AGAGTTGGNN                         NTACTCCAAC                                   TGAAATGTTA                                             AGGAAGAAGA                                                       1620TAGATCCAAT     TAAAAAAAAT               TAAAACCAAT                         TTAAAAAAAA                                   AAAAGAACAC                                             AGGAGATTCC                                                       1680AGTCTACTTG     AGTTAGCATA               ATACAGAAGT                         CCCCTCTACT                                   TTAACTTTTA                                             CAAAAAAGTA                                                       1740ACCTGAACTA     ATCTGATGTT               AACCAATGTA                         TTTATTTCTG                                   TGGTTCTGTT                                             TCCTTGTTCC                                                       1800AATTTGACAA     AACCCACTGT               TCTTGTATTG                         TATTGCCAGG                                   GGGGAGCTAT                                             CACTGTACTT                                                       1860GTAGAGTGGT     GCTGCTTTAA               GTTCATAAAT                         CACAAATAAA                                   AGCCAATTAG                                             CTCTATAACT                                                       1920AAAAAAAAAA     AAAAAAAAAA               AAAAAAAAAA                         AAAAAAAAAA                                   AAAA                1964__________________________________________________________________________ 
    
     
         __________________________________________________________________________SEQUENCE LISTING__________________________________________________________________________(1)  GENERAL INFORMATION:(i)  APPLICANT:         BARNETT, THOMAS R         ELTING, JAMES J         KAMARCK, MICHAEL E         KRETSCHMER, A W(ii) TITLE OF INVENTION: CDNAS CODING FOR MEMBERS OF THECARCINOEMBRYONIC ANTIGEN FAMILY(iii)NUMBER OF SEQUENCES: 1(iv) CORRESPONDENCE ADDRESS:(A)     ADDRESSEE: SPRUNG HORN KRAMER &amp; WOODS(B)     STREET: 1140 AVENUE OF THE AMERICAS(C)     CITY: NEW YORK(D)     STATE: NEW YORK(E)     COUNTRY: U.S.A.(F)     ZIP: 10036(v)  COMPUTER READABLE FORM:(A)     MEDIUM TYPE: Floppy disk(B)     COMPUTER: IBM PC compatible(C)     OPERATING SYSTEM: PC-DOS/MS-DOS(D)     SOFTWARE: PatentIn Release #1.0, Version #1.25(vi) CURRENT APPLICATION DATA:(A)     APPLICATION NUMBER: US 07/760,031(B)     FILING DATE: 13-NOV-1991(C)     CLASSIFICATION: UNASSIGNED(viii)ATTORNEY/AGENT INFORMATION:(A)     NAME: VASTA JR, VINCENT J(B)     REGISTRATION NUMBER: 26,655(C)     REFERENCE/DOCKET NUMBER: MDI 242.5-VJV(ix) TELECOMMUNICATION INFORMATION:(A)     TELEPHONE: (212) 391-0520(B)     TELEFAX: (212) 382-0949(C)     TELEX: 423092 NYP UI(2)  INFORMATION FOR SEQ ID NO:5:(i)  SEQUENCE CHARACTERISTICS:(A)     LENGTH: 3173 base pairs(B)     TYPE: nucleic acid(C)     STRANDEDNESS: double(D)     TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(iii)HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(vi) ORIGINAL SOURCE:(A)     ORGANISM: HOMO SAPIENS(vii)IMMEDIATE SOURCE:(B)     CLONE: CEA-(e) [E22](xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:CAGCCGTGCT     CGAAGCGTTC               CTGGAGCCCA                         AGCTCTCCTC                                   CACAGGTGAA                                             GACAGGGCCA                                                       60GCAGGAGACA     CCATGGGGCA               CCTCTCAGCC                         CCACTTCACA                                   GAGTGCGTGT                                             ACCCTGGCAG                                                       120GGGCTTCTGC     TCACAGCCTC               ACTTCTAACC                         TTCTGGAACC                                   CGCCCACCAC                                             TGCCCAGCTC                                                       180ACTACTGAAT     CCATGCCATT               CAATGTTGCA                         GAGGGGAAGG                                   AGGTTCTTCT                                             CCTTGTCCAC                                                       240AATCTGCCCC     AGCAACTTTT               TGGCTACAGC                         TGGTACAAAG                                   GGGAAAGAGT                                             GGATGGCAAC                                                       300CGTCAAATTG     TAGGATATGC               AATAGGAACT                         CAACAAGCTA                                   CCCCAGGGCC                                             CGCAAACAGC                                                       360GGTCGAGAGA     CAATATACCC               CAATGCATCC                         CTGCTGATCC                                   AGAACGTCAC                                             CCAGAATGAC                                                       420ACAGGATTCT     ACACCCTACA               AGTCATAAAG                         TCAGATCTTG                                   TGAATGAAGA                                             AGCAACTGGA                                                       480CAGTTCCATG     TATACCCGGA               GCTGCCCAAG                         CCCTCCATCT                                   CCAGCAACAA                                             CTCCAACCCT                                                       540GTGGAGGACA     AGGATGCTGT               GGCCTTCACC                         TGTGAACCTG                                   AGACTCAGGA                                             CACAACCTAC                                                       600CTGTGGTGGA     TAAACAATCA               GAGCCTCCCG                         GTCAGTCCCA                                   GGCTGCAGCT                                             GTCCAATGGC                                                       660AACAGGACCC     TCACTCTACT               CAGTGTCACA                         AGGAATGACA                                   CAGGACCCTA                                             TGAGTGTGAA                                                       720ATACAGAACC     CAGTGAGTGC               GAACCGCAGT                         GACCCAGTCA                                   CCTTGAATGT                                             CACCTATGGC                                                       780CCGGACACCC     CCACCATTTC               CCCTTCAGAC                         ACCTATTACC                                   GTCCAGGGGC                                             AAACCTCAGC                                                       840CTCTCCTGCT     ATGCAGCCTC               TAACCCACCT                         GCACAGTACT                                   CCTGGCTTAT                                             CAATGGAACA                                                       900TTCCAGCAAA     GCACACAAGA               GCTCTTTATC                         CCTAACATCA                                   CTGTGAATAA                                             TAGTGGATCC                                                       960TATACCTGCC     ACGCCAATAA               CTCAGTCACT                         GGCTGCAACA                                   GGACCACAGT                                             CAAGACGATC                                                       1020ATAGTCACTG     ATAATGCTCT               ACCACAAGAA                         AATGGCCTCT                                   CACCTGGGGC                                             CATTGCTGGC                                                       1080ATTGTGATTG     GAGTAGTGGC               CCTGGTTGCT                         CTGATAGCAG                                   TAGCCCTGGC                                             ATGTTTTCTG                                                       1140CATTTCGGGA     AGACCGGCAG               GGCAAGCGAC                         CAGCGTGATC                                   TCACAGAGCA                                             CAAACCCTCA                                                       1200GTCTCCAACC     ACACTCAGGA               CCACTCCAAT                         GACCCACCTA                                   ACAAGATGAA                                             TGAAGTTACT                                                       1260TATTCTACCC     TGAACTTTGA               AGCCCAGCAA                         CCCACACAAC                                   CAACTTCAGC                                             CTCCCCATCC                                                       1320CTAACAGCCA     CAGAAATAAT               TTATTCAGAA                         GTAAAAAAGC                                   AGTAATGAAA                                             CCTGTCCTGC                                                       1380TCACTGCAGT     GCTGATGTAT               TTCAAGTCTC                         TCACCCTCAT                                   CACTAGGAGA                                             TTCCTTTCCC                                                       1440CTGTAGGGTA     GAGGGGTGGG               GACAGAAACA                         ACTTTCTCCT                                   ACTCTTCCTT                                             CCTAATAGGC                                                       1500ATCTCCAGGC     TGCCTGGTCA               CTGCCCCTCT                         CTCAGTGTCA                                   ATAGATGAAA                                             GTACATTGGG                                                       1560AGTCTGTAGG     AAACCCAACC               TTCTTGTCAT                         TGAAATTTGG                                   CAAAGCTGAC                                             TTTGGGAAAG                                                       1620AGGGACCAGA     ACTTCCCCTC               CCTTCCCCTT                         TTCCCAACCT                                   GGACTTGTTT                                             TAAACTTGCC                                                       1680TGTTCAGAGC     ACTCATTCCT               TCCCACCCCC                         AGTCCTGTCC                                   TATCACTCTA                                             ATTCGGATTT                                                       1740GCCATAGCCT     TGAGGTTATG               TCCTTTTCCA                         TTAAGTACAT                                   GTGCCAGGAA                                             ACAGCGAGAG                                                       1800AGAGAAAGTA     AACGGCAGTA               ATGCTTCTCC                         TATTTCTCCA                                   AAGCCTTGTG                                             TGAACTAGCA                                                       1860AAGAGAAGAA     AATCAAATAT               ATAACCAATA                         GTGAAATGCC                                   ACAGGTTTGT                                             CCACTGTCAG                                                       1920GGTTGTCTAC     CTGTAGGATC               AGGGTCTAAG                         CACCTTGGTG                                   CTTAGCTAGA                                             ATACCACCTA                                                       1980ATCCTTCTGG     CAAGCCTGTC               TTCAGAGAAC                         CCACTAGAAG                                   CAACTAGGAA                                             AAATCACTTG                                                       2040CCAAAATCCA     AGGCAATTCC               TGATGGAAAA                         TGCAAAAGCA                                   CATATATGTT                                             TTAATATCTT                                                       2100TATGGGCTCT     GTTCAAGGCA               GTGCTGAGAG                         GGAGGGGTTA                                   TAGCTTCAGG                                             AGGGAACCAG                                                       2160CTTCTGATAA     ACACAATCTG               CTAGGAACTT                         GGGAAAGGAA                                   TCAGAGAGCT                                             GCCCTTCAGC                                                       2220GATTATTTAA     ATTATTGTTA               AAGAATACAC                         AATTTGGGGT                                   ATTGGGATTT                                             TTCTCCTTTT                                                       2280CTCTGAGACA     TTCCACCATT               TTAATTTTTG                         TAACTGCTTA                                   TTTATGTGAA                                             AAGGGTTATT                                                       2340TTTACTTAGC     TTAGCTATGT               CAGCCAATCC                         GATTGCCTTA                                   GGTGAAAGAA                                             ACCACCGAAA                                                       2400TCCCTCAGGT     CCCTTGGTCA               GGAGCCTCTC                         AAGATTTTTT                                   TTGTCAGAGG                                             CTCCAAATAG                                                       2460AAAATAAGAA     AAGGTTTTCT               TCATTCATGG                         CTAGAGCTAG                                   ATTTAACTCA                                             GTTTCTAGGC                                                       2520ACCTCAGACC     AATCATCAAC               TACCATTCTA                         TTCCATGTTT                                   GCACCTGTGC                                             ATTTTCTGTT                                                       2580TGCCCCCATT     CACTTTGTCA               GGAAACCTTG                         GCCTCTGCTA                                   AGGTGTATTT                                             GGTCCTTGAG                                                       2640AAGTGGGAGC     ACCCTACAGG               GACACTATCA                         CTCATGCTGG                                   TGGCATTGTT                                             TACAGCTAGA                                                       2700AAGCTGCACT     GGTGCTAATG               CCCCTTGGGA                         AATGGGGCTG                                   TGAGGAGGAG                                             GATTATAACT                                                       2760TAGGCCTAGC     CTCTTTTAAC               AGCCTCTGAA                         ATTTATCTTT                                   TCTTCTATGG                                             GGTCTATAAA                                                       2820TGTATCTTAT     AATAAAAAGG               AAGGACAGGA                         GGAAGACAGG                                   CAAATGTACT                                             TCTCACCCAG                                                       2880TCTTCTACAC     AGATGGAATC               TCTTTGGGGC                         TAAGAGAAAG                                   GTTTTATTCT                                             ATATTGCTTA                                                       2940CCTGATCTCA     TGTTAGGCCT               AAGAGGCTTT                         CTCCAGGAGG                                   ATTAGCTTGG                                             AGTTCTCTAT                                                       3000ACTCAGGTAC     CTCTTTCAGG               GTTTTCTAAC                         CCTGACACGG                                   ACTGTGCATA                                             CTTTCCCTCA                                                       3060TCCATGCTGT     GCTGTGTTAT               TTAATTTTTC                         CTGGCTAAGA                                   TCATGTCTGA                                             ATTATGTATG                                                       3120AAAATTATTC     TATGTTTTTA               TAATAAAAAT                         AATATATCAG                                   ACATCGAAAA                                             AAA       3173__________________________________________________________________________ 
    
     
         __________________________________________________________________________SEQUENCE LISTING__________________________________________________________________________(1)  GENERAL INFORMATION:(i)  APPLICANT:         BARNETT, THOMAS R         ELTING, JAMES J         KAMARCK, MICHAEL E         KRETSCHMER, A W(ii) TITLE OF INVENTION: CDNAS CODING FOR MEMBERS OF THECARCINOEMBRYONIC ANTIGEN FAMILY(iii)NUMBER OF SEQUENCES: 1(iv) CORRESPONDENCE ADDRESS:(A)     ADDRESSEE: SPRUNG HORN KRAMER &amp; WOODS(B)     STREET: 1140 AVENUE OF THE AMERICAS(C)     CITY: NEW YORK(D)     STATE: NEW YORK(E)     COUNTRY: U.S.A.(F)     ZIP: 10036(v)  COMPUTER READABLE FORM:(A)     MEDIUM TYPE: Floppy disk(B)     COMPUTER: IBM PC compatible(C)     OPERATING SYSTEM: PC-DOS/MS-DOS(D)     SOFTWARE: PatentIn Release #1.0, Version #1.25(vi) CURRENT APPLICATION DATA:(A)     APPLICATION NUMBER: US 07/760,031(B)     FILING DATE: 13-NOV-1991(C)     CLASSIFICATION: UNASSIGNED(viii)ATTORNEY/AGENT INFORMATION:(A)     NAME: VASTA JR, VINCENT J(B)     REGISTRATION NUMBER: 26,655(C)     REFERENCE/DOCKET NUMBER: MDI 242.5-VJV(ix) TELECOMMUNICATION INFORMATION:(A)     TELEPHONE: (212) 391-0520(B)     TELEFAX: (212) 382-0949(C)     TELEX: 423092 NYP UI(2)  INFORMATION FOR SEQ ID NO:6:(i)  SEQUENCE CHARACTERISTICS:(A)     LENGTH: 1630 base pairs(B)     TYPE: nucleic acid(C)     STRANDEDNESS: double(D)     TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(iii)HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(vi) ORIGINAL SOURCE:(A)     ORGANISM: HOMO SAPIENS(vii)IMMEDIATE SOURCE:(B)     CLONE: CEA-(f) [HT-6](xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:CAGCCGTGCT     CGAAGCGTTC               CTGGAGCCCA                         AGCTCTCCTC                                   CACAGGTGAA                                             GACAGGGCCA                                                       60GCAGGAGACA     CCATGGGGCA               CCTCTCAGCC                         CCACTTCACA                                   GAGTGCGTGT                                             ACCCTGGCAG                                                       120GGGCTTCTGC     TCACAGCCTC               ACTTCTAACC                         TTCTGGAACC                                   CGCCCACCAC                                             TGCCCAGCTC                                                       180ACTACTGAAT     CCATGCCATT               CAATGTTGCA                         GAGGGGAAGG                                   AGGTTCTTCT                                             CCTTGTCCAC                                                       240AATCTGCCCC     AGCAACTTTT               TGGCTACAGC                         TGGTACAAAG                                   GGGAAAGAGT                                             GGATGGCAAC                                                       300CGTCAAATTG     TAGGATATGC               AATAGGAACT                         CAACAAGCTA                                   CCCCAGGGCC                                             CGCAAACAGC                                                       360GGTCGAGAGA     CAATATACCC               CAATGCATCC                         CTGCTGATCC                                   AGAACGTCAC                                             CCAGAATGAC                                                       420ACAGGATTCT     ACACCCTACA               AGTCATAAAG                         TCAGATCTTG                                   TGAATGAAGA                                             AGCAACTGGA                                                       480CAGTTCCATG     TATACCCGGA               GCTGCCCAAG                         CCCTCCATCT                                   CCAGCAACAA                                             CTCCAACCCT                                                       540GTGGAGGACA     AGGATGCTGT               GGCCTTCACC                         TGTGAACCTG                                   AGACTCAGGA                                             CACAACCTAC                                                       600CTGTGGTGGA     TAAACAATCA               GAGCCTCCCG                         GTCAGTCCCA                                   GGCTGCAGCT                                             GTCCAATGGC                                                       660AACAGGACCC     TCACTCTACT               CAGTGTCACA                         AGGAATGACA                                   CAGGACCCTA                                             TGAGTGTGAA                                                       720ATACAGAACC     CAGTGAGTGC               GAACCGCAGT                         GACCCAGTCA                                   CCTTGAATGT                                             CACCTATGGC                                                       780CCGGACACCC     CCACCATTTC               CCCTTCAGAC                         ACCTATTACC                                   GTCCAGGGGC                                             AAACCTCAGC                                                       840CTCTCCTGCT     ATGCAGCCTC               TAACCCACCT                         GCACAGTACT                                   CCTGGCTTAT                                             CAATGGAACA                                                       900TTCCAGCAAA     GCACACAAGA               GCTCTTTATC                         CCTAACATCA                                   CTGTGAATAA                                             TAGTGGATCC                                                       960TATACCTGCC     ACGCCAATAA               CTCAGTCACT                         GGCTGCAACA                                   GGACCACAGT                                             CAAGACGATC                                                       1020ATAGTCACTG     AGCTAAGTCC               AGTAGTAGCA                         AAGCCCCAAA                                   TCAAAGCCAG                                             CAAGACCACA                                                       1080GTCACAGGAG     ATAAGGACTC               TGTGAACCTG                         ACCTGCTCCA                                   CAAATGACAC                                             TGGAATCTCC                                                       1140ATCCGTTGGT     TCTTCAAAAA               CCAGAGTCTC                         CCGTCCTCGG                                   AGAGGATGAA                                             GCTGTCCCAG                                                       1200GGCAACACCA     CCCTCAGCAT               AAACCCTGTC                         AAGAGGGAGG                                   ATGCTGGGAC                                             GTATTGGTGT                                                       1260GAGGTCTTCA     ACCCAATCAG               TAAGAACCAA                         AGCGACCCCA                                   TCATGCTGAA                                             CGTAAACTAT                                                       1320AATGCTCTAC     CACAAGAAAA               TGGCCTCTCA                         CCTGGGGCCA                                   TTGCTGGCAT                                             TGTGATTGGA                                                       1380GTAGTGGCCC     TGGTTGCTCT               GATAGCAGTA                         GCCCTGGCAT                                   GTTTTCTGCA                                             TTTCGGGAAG                                                       1440ACCGGCAGCT     CAGGACCACT               CCAATGACCC                         ACCTAACAAG                                   ATGAATGAAG                                             TTACTTATTC                                                       1500TACCCTGAAC     TTTGAAGCCC               AGCAACCCAC                         ACAACCAACT                                   TCAGCCTCCC                                             CATCCCTAAC                                                       1560AGCCACAGAA     ATAATTTATT               CAGAAGTAAA                         AAAGCAGTAA                                   TGAAACCTGA                                             AAAAAAAAAA                                                       1620AAAAAAAAAA                                                  1630__________________________________________________________________________ 
    
     
         __________________________________________________________________________SEQUENCE LISTING__________________________________________________________________________(1)  GENERAL INFORMATION:(i)  APPLICANT:         BARNETT, THOMAS R         ELTING, JAMES J         KAMARCK, MICHAEL E         KRETSCHMER, A W(ii) TITLE OF INVENTION: CDNAS CODING FOR MEMBERS OF THECARCINOEMBRYONIC ANTIGEN FAMILY(iii)NUMBER OF SEQUENCES: 1(iv) CORRESPONDENCE ADDRESS:(A)     ADDRESSEE: SPRUNG HORN KRAMER &amp; WOODS(B)     STREET: 1140 AVENUE OF THE AMERICAS(C)     CITY: NEW YORK(D)     STATE: NEW YORK(E)     COUNTRY: U.S.A.(F)     ZIP: 10036(v)  COMPUTER READABLE FORM:(A)     MEDIUM TYPE: Floppy disk(B)     COMPUTER: IBM PC compatible(C)     OPERATING SYSTEM: PC-DOS/MS-DOS(D)     SOFTWARE: PatentIn Release #1.0, Version #1.25(vi) CURRENT APPLICATION DATA:(A)     APPLICATION NUMBER: US 07/760,031(B)     FILING DATE: 13-NOV-1991(C)     CLASSIFICATION: UNASSIGNED(viii)ATTORNEY/AGENT INFORMATION:(A)     NAME: VASTA JR, VINCENT J(B)     REGISTRATION NUMBER: 26,655(C)     REFERENCE/DOCKET NUMBER: MDI 242.5-VJV(ix) TELECOMMUNICATION INFORMATION:(A)     TELEPHONE: (212) 391-0520(B)     TELEFAX: (212) 382-0949(C)     TELEX: 423092 NYP UI(2)  INFORMATION FOR SEQ ID NO:7:(i)  SEQUENCE CHARACTERISTICS:(A)     LENGTH: 1339 base pairs(B)     TYPE: nucleic acid(C)     STRANDEDNESS: double(D)     TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(iii)HYPOTHETICAL: YES(iv) ANTI-SENSE: NO(vii)IMMEDIATE SOURCE:(B)     CLONE: CEA-(g)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:CAGCCGTGCT     CGAAGCGTTC               CTGGAGCCCA                         AGCTCTCCTC                                   CACAGGTGAA                                             GACAGGGCCA                                                       60GCAGGAGACA     CCATGGGGCA               CCTCTCAGCC                         CCACTTCACA                                   GAGTGCGTGT                                             ACCCTGGCAG                                                       120GGGCTTCTGC     TCACAGCCTC               ACTTCTAACC                         TTCTGGAACC                                   CGCCCACCAC                                             TGCCCAGCTC                                                       180ACTACTGAAT     CCATGCCATT               CAATGTTGCA                         GAGGGGAAGG                                   AGGTTCTTCT                                             CCTTGTCCAC                                                       240AATCTGCCCC     AGCAACTTTT               TGGCTACAGC                         TGGTACAAAG                                   GGGAAAGAGT                                             GGATGGCAAC                                                       300CGTCAAATTG     TAGGATATGC               AATAGGAACT                         CAACAAGCTA                                   CCCCAGGGCC                                             CGCAAACAGC                                                       360GGTCGAGAGA     CAATATACCC               CAATGCATCC                         CTGCTGATCC                                   AGAACGTCAC                                             CCAGAATGAC                                                       420ACAGGATTCT     ACACCCTACA               AGTCATAAAG                         TCAGATCTTG                                   TGAATGAAGA                                             AGCAACTGGA                                                       480CAGTTCCATG     TATACCCGGA               GCTGCCCAAG                         CCCTCCATCT                                   CCAGCAACAA                                             CTCCAACCCT                                                       540GTGGAGGACA     AGGATGCTGT               GGCCTTCACC                         TGTGAACCTG                                   AGACTCAGGA                                             CACAACCTAC                                                       600CTGTGGTGGA     TAAACAATCA               GAGCCTCCCG                         GTCAGTCCCA                                   GGCTGCAGCT                                             GTCCAATGGC                                                       660AACAGGACCC     TCACTCTACT               CAGTGTCACA                         AGGAATGACA                                   CAGGACCCTA                                             TGAGTGTGAA                                                       720ATACAGAACC     CAGTGAGTGC               GAACCGCAGT                         GACCCAGTCA                                   CCTTGAATGT                                             CACCTATGGC                                                       780CCGGACACCC     CCACCATTTC               CCCTTCAGAC                         ACCTATTACC                                   GTCCAGGGGC                                             AAACCTCAGC                                                       840CTCTCCTGCT     ATGCAGCCTC               TAACCCACCT                         GCACAGTACT                                   CCTGGCTTAT                                             CAATGGAACA                                                       900TTCCAGCAAA     GCACACAAGA               GCTCTTTATC                         CCTAACATCA                                   CTGTGAATAA                                             TAGTGGATCC                                                       960TATACCTGCC     ACGCCAATAA               CTCAGTCACT                         GGCTGCAACA                                   GGACCACAGT                                             CAAGACGATC                                                       1020ATAGTCACTG     ATAATGCTCT               ACCACAAGAA                         AATGGCCTCT                                   CACCTGGGGC                                             CATTGCTGGC                                                       1080ATTGTGATTG     GAGTAGTGGC               CCTGGTTGCT                         CTGATAGCAG                                   TAGCCCTGGC                                             ATGTTTTCTG                                                       1140CATTTCGGGA     AGACCGGCAG               CTCAGGACCA                         CTCCAATGAC                                   CCACCTAACA                                             AGATGAATGA                                                       1200AGTTACTTAT     TCTACCCTGA               ACTTTGAAGC                         CCAGCAACCC                                   ACACAACCAA                                             CTTCAGCCTC                                                       1260CCCATCCCTA     ACAGCCACAG               AAATAATTTA                         TTCAGAAGTA                                   AAAAAGCAGT                                             AATGAAACCT                                                       1320GAAAAAAAAA     AAAAAAAAA                                         1339__________________________________________________________________________ 
    
     
         __________________________________________________________________________SEQUENCE LISTING__________________________________________________________________________(1)  GENERAL INFORMATION:(i)  APPLICANT:         BARNETT, THOMAS R         ELTING, JAMES J         KAMARCK, MICHAEL E         KRETSCHMER, A W(ii) TITLE OF INVENTION: CDNAS CODING FOR MEMBERS OF THECARCINOEMBRYONIC ANTIGEN FAMILY(iii)NUMBER OF SEQUENCES: 1(iv) CORRESPONDENCE ADDRESS:(A)     ADDRESSEE: SPRUNG HORN KRAMER &amp; WOODS(B)     STREET: 1140 AVENUE OF THE AMERICAS(C)     CITY: NEW YORK(D)     STATE: NEW YORK(E)     COUNTRY: U.S.A.(F)     ZIP: 10036(v)  COMPUTER READABLE FORM:(A)     MEDIUM TYPE: Floppy disk(B)     COMPUTER: IBM PC compatible(C)     OPERATING SYSTEM: PC-DOS/MS-DOS(D)     SOFTWARE: PatentIn Release #1.0, Version #1.25(vi) CURRENT APPLICATION DATA:(A)     APPLICATION NUMBER: US 07/760,031(B)     FILING DATE: 13-NOV-1991(C)     CLASSIFICATION: UNASSIGNED(viii)ATTORNEY/AGENT INFORMATION:(A)     NAME: VASTA JR, VINCENT J(B)     REGISTRATION NUMBER: 26,655(C)     REFERENCE/DOCKET NUMBER: MDI 242.5-VJV(ix) TELECOMMUNICATION INFORMATION:(A)     TELEPHONE: (212) 391-0520(B)     TELEFAX: (212) 382-0949(C)     TELEX: 423092 NYP UI(2)  INFORMATION FOR SEQ ID NO:8:(i)  SEQUENCE CHARACTERISTICS:(A)     LENGTH: 2010 base pairs(B)     TYPE: nucleic acid(C)     STRANDEDNESS: double(D)     TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(iii)HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(vi) ORIGINAL SOURCE:(A)     ORGANISM: HOMO SAPIENS(vii)IMMEDIATE SOURCE:(B)     CLONE: KGCEA1(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:ACAGCACAGC     TGACAGCCGT               ACTCAGGAAG                         CTTCTGGATC                                   CTAGGCTTAT                                             CTCCACAGAG                                                       60GAGAACACAC     AAGCAGCAGA               GACCATGGGG                         CCCCTCTCAG                                   CCCCTCCCTG                                             CACACACCTC                                                       120ATCACTTGGA     AGGGGGTCCT               GCTCACAGCA                         TCACTTTTAA                                   ACTTCTGGAA                                             TCCGCCCACA                                                       180ACTGCCCAAG     TCACGATTGA               AGCCCAGCCA                         CCCAAAGTTT                                   CTGAGGGGAA                                             GGATGTTCTT                                                       240CTACTTGTCC     ACAATTTGCC               CCAGAATCTT                         GCTGGCTACA                                   TTTGGTACAA                                             AGGGCAAATG                                                       300ACATACGTCT     ACCATTACAT               TACATCATAT                         GTAGTAGACG                                   GTCAAAGAAT                                             TATATATGGG                                                       360CCTGCATACA     GTGGAAGAGA               AAGAGTATAT                         TCCAATGCAT                                   CCCTGCTGAT                                             CCAGAATGTC                                                       420ACGCAGGAGG     ATGCAGGATC               CTACACCTTA                         CACATCATAA                                   AGCGACGCGA                                             TGGGACTGGA                                                       480GGAGTAACTG     GACATTTCAC               CTTCACCTTA                         CACCTGGAGA                                   CTCCCAAGCC                                             CTCCATCTCC                                                       540AGCAGCAACT     TAAATCCCAG               GGAGGCCATG                         GAGGCTGTGA                                   TCTTAACCTG                                             TGATCCTGCG                                                       600ACTCCAGCCG     CAAGCTACCA               GTGGTGGATG                         AATGGTCAGA                                   GCCTCCCTAT                                             GACTCACAGG                                                       660TTGCAGCTGT     CCAAAACCAA               CAGGACCCTC                         TTTATATTTG                                   GTGTCACAAA                                             GTATATTGCA                                                       720GGACCCTATG     AATGTGAAAT               ACGGAACCCA                         GTGAGTGCCA                                   GCCGCAGTGA                                             CCCAGTCACC                                                       780CTGAATCTCC     TCCCAAAGCT               GTCCAAGCCC                         TACATCACAA                                   TCAACAACTT                                             AAACCCCAGA                                                       840GAGAATAAGG     ATGTCTTAAC               CTTCACCTGT                         GAACCTAAGA                                   GTGAGAACTA                                             CACCTACATT                                                       900TGGTGGCTAA     ATGGTCAGAG               CCTCCCTGTC                         AGTCCCAGGG                                   TAAAGCGACC                                             CATTGAAAAC                                                       960AGGATCCTCA     TTCTACCCAA               TGTCACGAGA                         AATGAAACAG                                   GACCTTATCA                                             ATGTGAAATA                                                       1020CGGGACCGAT     ATGGTGGCAT               CCGCAGTGAC                         CCAGTCACCC                                   TGAATGTCCT                                             CTATGGTCCA                                                       1080GACCTCCCCA     GCATTTACCC               TTCATTCACC                         TATTACCGTT                                   CAGGAGAAAA                                             CCTCTACTTT                                                       1140TCCTGCTTCG     GTGAGTCTAA               CCCACGGGCA                         CAATATTCTT                                   GGACAATTAA                                             TGGGAAGTTT                                                       1200CAGCTATCAG     GACAAAAGCT               CTCTATCCCC                         CAAATAACTA                                   CAAAGCATAG                                             TGGGCTCTAT                                                       1260GCTTGCTCTG     TTCGTAACTC               AGCCACTGGC                         AAGGAAAGCT                                   CCAAATCCAT                                             CACAGTCAAA                                                       1320GTCTCTGACT     GGATATTACC               CTGAATTCTA                         CTAGTTCCTC                                   CAATTCCATT                                             TTCTCCCATG                                                       1380GAATCACGAA     GAGCAAGACC               CACTCTGTTC                         CAGAAGCCCT                                   ATAATCTGGA                                             GGTGGACAAC                                                       1440TCGATGTAAA     TTTCATGGGA               AAACCCTTGT                         ACCTGACATG                                   TGAGCCACTC                                             AGAACTCACC                                                       1500AAAATGTTCG     ACACCATAAC               AACAGCTACT                         CAAACTGTAA                                   ACCAGGATAA                                             GAAGTTGATG                                                       1560ACTTCACACT     GTGGACAGTT               TTTCAAAGAT                         GTCATAACAA                                   GACTCCCCAT                                             CATGACAAGG                                                       1620CTCCACCCTC     TACTGTCTGC               TCATGCCTGC                         CTCTTTCACT                                   TGGCAGGATA                                             ATGCAGTCAT                                                       1680TAGAATTTCA     CATGTAGTAG               CTTCTGAGGG                         TAACAACACA                                   CTGTCAGATA                                             TGTCATCTCA                                                       1740ACCTCAAACT     TTTACGTAAC               ATCTCAGGGA                         AATGTGGCTC                                   TCTCCATCTT                                             GCATACAGGG                                                       1800CTCCCAATAG     AAATGAACAC               AGAGATATTG                         CCTGTGTGTT                                   TGCAGAGAAG                                             ATGGTTTCTA                                                       1860TAAAGAGTAG     GAAAGCTGAA               ATTATAGTAG                         AGTCTCCTTT                                   AAATGCACAT                                             TGTGTGGATG                                                       1920GCTCTCACCA     TTTCCTAAGA               GATACAGTGT                         AAAAACGTGA                                   CAGTAATACT                                             GATTCTAGCA                                                       1980GAATAAACAT     GTACCACATT               TGCAAAAAAA                              2010__________________________________________________________________________ 
    
     
         __________________________________________________________________________SEQUENCE LISTING__________________________________________________________________________(1)  GENERAL INFORMATION:(i)  APPLICANT:         BARNETT, THOMAS R         ELTING, JAMES J         KAMARCK, MICHAEL E         KRETSCHMER, A W(ii) TITLE OF INVENTION: CDNAS CODING FOR MEMBERS OF THECARCINOEMBRYONIC ANTIGEN FAMILY(iii)NUMBER OF SEQUENCES: 1(iv) CORRESPONDENCE ADDRESS:(A)     ADDRESSEE: SPRUNG HORN KRAMER &amp; WOODS(B)     STREET: 1140 AVENUE OF THE AMERICAS(C)     CITY: NEW YORK(D)     STATE: NEW YORK(E)     COUNTRY: U.S.A.(F)     ZIP: 10036(v)  COMPUTER READABLE FORM:(A)     MEDIUM TYPE: Floppy disk(B)     COMPUTER: IBM PC compatible(C)     OPERATING SYSTEM: PC-DOS/MS-DOS(D)     SOFTWARE: PatentIn Release #1.0, Version #1.25(vi) CURRENT APPLICATION DATA:(A)     APPLICATION NUMBER: US 07/760,031(B)     FILING DATE: 13-NOV-1991(C)     CLASSIFICATION: UNASSIGNED(viii)ATTORNEY/AGENT INFORMATION:(A)     NAME: VASTA JR, VINCENT J(B)     REGISTRATION NUMBER: 26,655(C)     REFERENCE/DOCKET NUMBER: MDI 242.5-VJV(ix) TELECOMMUNICATION INFORMATION:(A)     TELEPHONE: (212) 391-0520(B)     TELEFAX: (212) 382-0949(C)     TELEX: 423092 NYP UI(2)  INFORMATION FOR SEQ ID NO:9:(i)  SEQUENCE CHARACTERISTICS:(A)     LENGTH: 1591 base pairs(B)     TYPE: nucleic acid(C)     STRANDEDNESS: double(D)     TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(iii)HYPOTHETICAL: NO(iv) ANTI-SENSE: NO(vi) ORIGINAL SOURCE:(A)     ORGANISM: homo sapiens(vii)IMMEDIATE SOURCE:(B)     CLONE: KGCEA2(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:GGGTGGATCC     TAGGCTCATC               TCCATAGGGG                         AGAACACACA                                   TACAGCAGAG                                             ACCATGGGAC                                                       60CCCTCTCAGC     CCCTCCCTGC               ACTCAGCACA                         TCACCTGGAA                                   GGGGCTCCTG                                             CTCACAGCAT                                                       120CACTTTTAAA     CTTCTGGAAC               CTGCCCACCA                         CTGCCCAAGT                                   AATAATTGAA                                             GCCCAGCCAC                                                       180CCAAAGTTTC     TGAGGGGAAG               GATGTTCTTC                         TACTTGTCCA                                   CAATTTGCCC                                             CAGAATCTTA                                                       240CTGGCTACAT     CTGGTACAAA               GGGCAAATGA                         CGGACCTCTA                                   CCATTACATT                                             ACATCATATG                                                       300TAGTAGACGG     TCAAATTATA               TATGGGCCTG                         CCTACAGTGG                                   ACGAGAAACA                                             GTATATTCCA                                                       360ATGCATCCCT     GCTGATCCAG               AATGTCACAC                         AGGAGGATGC                                   AGGATCCTAC                                             ACCTTACACA                                                       420TCATAAAGCG     AGGCGATGGG               ACTGGAGGAG                         TAACTGGATA                                   TTTCACTGTC                                             ACCTTATACT                                                       480CGGAGACTCC     CAAGCGCTCC               ATCTCCAGCA                         GCAACTTAAA                                   CCCCAGGGAG                                             GTCATGGAGG                                                       540CTGTGCGCTT     AATCTGTGAT               CCTGAGACTC                         CGGATGCAAG                                   CTACCTGTGG                                             TTGCTGAATG                                                       600GTCAGAACCT     CCCTATGACT               CACAGGTTGC                         AGCTGTCCAA                                   AACCAACAGG                                             ACCCTCTATC                                                       660TATTTGGTGT     CACAAAGTAT               ATTGCAGGGC                         CCTATGAATG                                   TGAAATACGG                                             AGGGGAGTGA                                                       720GTGCCAGCCG     CAGTGACCCA               GTCACCCTGA                         ATCTCCTCCC                                   GAAGCTGCCC                                             ATGCCTTACA                                                       780TCACCATCAA     CAACTTAAAC               CCCAGGGAGA                         AGAAGGATGT                                   GTTAGCCTTC                                             ACCTGTGAAC                                                       840CTAAGAGTCG     GAACTACACC               TACATTTGGT                         GGCTAAATGG                                   TCAGAGCCTC                                             CCGGTCAGTC                                                       900CGAGGGTAAA     GCGACCCATT               GAAAACAGGA                         TACTCATTCT                                   ACCCAGTGTC                                             ACGAGAAATG                                                       960AAACAGGACC     CTATCAATGT               GAAATACGGG                         ACCGATATGG                                   TGGCATCCGC                                             AGTAACCCAG                                                       1020TCACCCTGAA     TGTCCTCTAT               GGTCCAGACC                         TCCCCAGAAT                                   TTACCCTTAC                                             TTCACCTATT                                                       1080ACCGTTCAGG     AGAAAACCTC               GACTTGTCCT                         GCTTTGCGGA                                   CTCTAACCCA                                             CCGGCAGAGT                                                       1140ATTTTTGGAC     AATTAATGGG               AAGTTTCAGC                         TATCAGGACA                                   AAAGCTCTTT                                             ATCCCCCAAA                                                       1200TTACTACAAA     TCATAGCGGG               CTCTATGCTT                         GCTCTGTTCG                                   TAACTCAGCC                                             ACTGGCAAGG                                                       1260AAATCTCCAA     ATCCATGATA               GTCAAAGTCT                         CTGGTCCCTG                                   CCATGGAAAC                                             CAGACAGAGT                                                       1320CTCATTAATG     GCTGCCACAA               TAGAGACACT                         GAGAAAAAGA                                   ACAGGTTGAT                                             ACCTTCATGA                                                       1380AATTCAAGAC     AAAGAAGAAA               AAGGCTCAAT                         GTTATTGGAC                                   TAAATAATCA                                             AAAGGATAAT                                                       1440GTTTTCATAA     TTTTTATTGG               AAAATGTGCT                         GATTCTTGGA                                   ATGTTTTATT                                             CTCCAGATTT                                                       1500ATGAACTTTT     TTTCTTCAGC               AATTGGTAAA                         GTATACTTTT                                   GTAAACAAAA                                             ATTGAAACAT                                                       1560TTGCTTTTGC     TCTCTATCTG               AGTGCCCCCC                         C                             1591__________________________________________________________________________ 
    
     
         __________________________________________________________________________SEQUENCE LISTING__________________________________________________________________________(1)  GENERAL INFORMATION:(i)  APPLICANT:         BARNETT, THOMAS R         ELTING, JAMES J         KAMARCK, MICHAEL E         KRETSCHMER, A W(ii) TITLE OF INVENTION: CDNAS CODING FOR MEMBERS OF THECARCINOEMBRYONIC ANTIGEN FAMILY(iii)NUMBER OF SEQUENCES: 1(iv) CORRESPONDENCE ADDRESS:(A)     ADDRESSEE: SPRUNG HORN KRAMER &amp; WOODS(B)     STREET: 1140 AVENUE OF THE AMERICAS(C)     CITY: NEW YORK(D)     STATE: NEW YORK(E)     COUNTRY: U.S.A.(F)     ZIP: 10036(v)  COMPUTER READABLE FORM:(A)     MEDIUM TYPE: Floppy disk(B)     COMPUTER: IBM PC compatible(C)     OPERATING SYSTEM: PC-DOS/MS-DOS(D)     SOFTWARE: PatentIn Release #1.0, Version #1.25(vi) CURRENT APPLICATION DATA:(A)     APPLICATION NUMBER: US 07/760,031(B)     FILING DATE: 13-NOV-1991(C)     CLASSIFICATION: UNASSIGNED(viii)ATTORNEY/AGENT INFORMATION:(A)     NAME: VASTA JR, VINCENT J(B)     REGISTRATION NUMBER: 26,655(C)     REFERENCE/DOCKET NUMBER: MDI 242.5-VJV(ix) TELECOMMUNICATION INFORMATION:(A)     TELEPHONE: (212) 391-0520(B)     TELEFAX: (212) 382-0949(C)     TELEX: 423092 NYP UI(2)  INFORMATION FOR SEQ ID NO:10:(i)  SEQUENCE CHARACTERISTICS:(A)     LENGTH: 702 amino acids(B)     TYPE: amino acid(D)     TOPOLOGY: linear(ii) MOLECULE TYPE: peptide(iii)HYPOTHETICAL: YES(iv) ANTI-SENSE: NO(vii)IMMEDIATE SOURCE:(B)     CLONE: TRANSLATED POLYPEPTIDE FROM CEA-(b) cDNA(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:Met   Glu Ser    Pro       Ser          Ala             Pro                Pro                   His                      Arg                         Trp                            Cys                               Ile                                  Pro                                     Trp                                        Gln1           5              10             15Arg   Leu Leu    Leu       Thr          Ala             Ser                Leu                   Leu                      Thr                         Phe                            Trp                               Asn                                  Pro                                     Pro                                        Thr    20             25             30Thr   Ala Lys    Leu       Thr          Ile             Glu                Ser                   Thr                      Pro                         Phe                            Asn                               Val                                  Ala                                     Glu                                        Gly 35             40             45Lys   Glu Val    Leu       Leu          Leu             Val                His                   Asn                      Leu                         Pro                            Gln                               His                                  Leu                                     Phe                                        Gly   50             55             60Tyr   Ser Trp    Tyr       Lys          Gly             Glu                Arg                   Val                      Asp                         Gly                            Asn                               Arg                                  Gln                                     Ile                                        Ile65             70             75             80Gly   Tyr Val    Ile       Gly          Thr             Gln                Gln                   Ala                      Thr                         Pro                            Gly                               Pro                                  Ala                                     Tyr                                        Ser       85             90             95Gly   Arg Glu    Ile       Ile          Tyr             Pro                Asn                   Ala                      Ser                         Leu                            Leu                               Ile                                  Gln                                     Asn                                        Ile    100            105            110Ile   Gln Asn    Asp       Thr          Gly             Phe                Tyr                   Thr                      Leu                         His                            Val                               Ile                                  Lys                                     Ser                                        Asp 115            120            125Leu   Val Asn    Glu       Glu          Ala             Thr                Gly                   Gln                      Phe                         Arg                            Val                               Tyr                                  Pro                                     Glu                                        Leu   130            135            140Pro   Lys Pro    Ser       Ile          Ser             Ser                Asn                   Asn                      Ser                         Lys                            Pro                               Val                                  Glu                                     Asp                                        Lys145            150            155            160Asp   Ala Val    Ala       Phe          Thr             Cys                Glu                   Pro                      Glu                         Thr                            Gln                               Asp                                  Ala                                     Thr                                        Tyr       165            170            175Leu   Trp Trp    Val       Asn          Asn             Gln                Ser                   Leu                      Pro                         Val                            Ser                               Pro                                  Arg                                     Leu                                        Gln    180            185            190Leu   Ser Asn    Gly       Asn          Arg             Thr                Leu                   Thr                      Leu                         Phe                            Asn                               Val                                  Thr                                     Arg                                        Asn 195            200            205Asp   Thr Ala    Ser       Tyr          Lys             Cys                Glu                   Thr                      Gln                         Asn                            Pro                               Val                                  Ser                                     Ala                                        Arg   210            215            220Arg   Ser Asp    Ser       Val          Ile             Leu                Asn                   Val                      Leu                         Tyr                            Gly                               Pro                                  Asp                                     Ala                                        Pro225            230            235            240Thr   Ile Ser    Pro       Leu          Asn             Thr                Ser                   Tyr                      Arg                         Ser                            Gly                               Glu                                  Asn                                     Leu                                        Asn       245            250            255Leu   Ser Cys    His       Ala          Ala             Ser                Asn                   Pro                      Pro                         Ala                            Gln                               Tyr                                  Ser                                     Trp                                        Phe    260            265            270Val   Asn Gly    Thr       Phe          Gln             Gln                Ser                   Thr                      Gln                         Glu                            Leu                               Phe                                  Ile                                     Pro                                        Asn 275            280            285Ile   Thr Val    Asn       Asn          Ser             Gly                Ser                   Tyr                      Thr                         Cys                            Gln                               Ala                                  His                                     Asn                                        Ser   290            295            300Asp   Thr Gly    Leu       Asn          Arg             Thr                Thr                   Val                      Thr                         Thr                            Ile                               Thr                                  Val                                     Tyr                                        Ala305            310            315            320Glu   Pro Pro    Lys       Pro          Phe             Ile                Thr                   Ser                      Asn                         Asn                            Ser                               Asn                                  Pro                                     Val                                        Glu       325            330            335Asp   Glu Asp    Ala       Val          Ala             Leu                Thr                   Cys                      Glu                         Pro                            Glu                               Ile                                  Gln                                     Asn                                        Thr    340            345            350Thr   Tyr Leu    Trp       Trp          Val             Asn                Asn                   Gln                      Ser                         Leu                            Pro                               Val                                  Ser                                     Pro                                        Arg 355            360            365Leu   Gln Leu    Ser       Asn          Asp             Asn                Arg                   Thr                      Leu                         Thr                            Leu                               Leu                                  Ser                                     Val                                        Thr   370            375            380Arg   Asn Asp    Val       Gly          Pro             Tyr                Glu                   Cys                      Gly                         Ile                            Gln                               Asn                                  Glu                                     Leu                                        Ser385            390            395            400Val   Asp His    Ser       Asp          Pro             Val                Ile                   Leu                      Asn                         Val                            Leu                               Tyr                                  Gly                                     Pro                                        Asp       405            410            415Asp   Pro Thr    Ile       Ser          Pro             Ser                Tyr                   Thr                      Tyr                         Tyr                            Arg                               Pro                                  Gly                                     Val                                        Asn    420            425            430Leu   Ser Leu    Ser       Cys          His             Ala                Ala                   Ser                      Asn                         Pro                            Pro                               Ala                                  Gln                                     Tyr                                        Ser 435            440            445Trp   Leu Ile    Asp       Gly          Asn             Ile                Gln                   Gln                      His                         Thr                            Gln                               Glu                                  Leu                                     Phe                                        Ile   450            455            460Ser   Asn Ile    Thr       Glu          Lys             Asn                Ser                   Gly                      Leu                         Tyr                            Thr                               Cys                                  Gln                                     Ala                                        Asn465            470            475            480Asn   Ser Ala    Ser       Gly          His             Ser                Arg                   Thr                      Thr                         Val                            Lys                               Thr                                  Ile                                     Thr                                        Val       485            490            495Ser   Ala Glu    Leu       Pro          Lys             Pro                Ser                   Ile                      Ser                         Ser                            Asn                               Asn                                  Ser                                     Lys                                        Pro    500            505            510Val   Glu Asp    Lys       Asp          Ala             Val                Ala                   Phe                      Thr                         Cys                            Glu                               Pro                                  Glu                                     Ala                                        Gln 515            520            525Asn   Thr Thr    Tyr       Leu          Trp             Trp                Val                   Asn                      Gly                         Gln                            Ser                               Leu                                  Pro                                     Val                                        Ser   530            535            540Pro   Arg Leu    Gln       Leu          Ser             Asn                Gly                   Asn                      Arg                         Thr                            Leu                               Thr                                  Leu                                     Phe                                        Asn545            550            555            560Val   Thr Arg    Asn       Asp          Ala             Arg                Ala                   Tyr                      Val                         Cys                            Gly                               Ile                                  Gln                                     Asn                                        Ser       565            570            575Val   Ser Ala    Asn       Arg          Ser             Asp                Pro                   Val                      Thr                         Leu                            Asp                               Val                                  Leu                                     Tyr                                        Gly    580            585            590Pro   Asp Thr    Pro       Ile          Ile             Ser                Pro                   Pro                      Asp                         Ser                            Ser                               Tyr                                  Leu                                     Ser                                        Gly 595            600            605Ala   Asn Leu    Asn       Leu          Ser             Cys                His                   Ser                      Ala                         Ser                            Asn                               Pro                                  Ser                                     Pro                                        Gln   610            615            620Tyr   Ser Trp    Arg       Ile          Asn             Gly                Ile                   Pro                      Gln                         Gln                            His                               Thr                                  Gln                                     Val                                        Leu625            630            635            640Phe   Ile Ala    Lys       Ile          Thr             Pro                Asn                   Asn                      Asn                         Gly                            Thr                               Tyr                                  Ala                                     Cys                                        Phe       645            650            655Val   Ser Asn    Leu       Ala          Thr             Gly                Arg                   Asn                      Asn                         Ser                            Ile                               Val                                  Lys                                     Ser                                        Ile    660            665            670Thr   Val Ser    Ala       Ser          Gly             Thr                Ser                   Pro                      Gly                         Leu                            Ser                               Ala                                  Gly                                     Ala                                        Thr 675            680            685Val   Gly Ile    Met       Ile          Gly             Val                Leu                   Val                      Gly                         Val                            Ala                               Leu                                  Ile   690            695            700__________________________________________________________________________ 
    
     
         __________________________________________________________________________SEQUENCE LISTING__________________________________________________________________________(1)  GENERAL INFORMATION(i)  APPLICANT:         BARNETT, THOMAS R         ELTING, JAMES J         KAMARCK, MICHAEL E         KRETSCHMER, A W(ii) TITLE OF INVENTION: CDNAS CODING FOR MEMBERS OF THECARCINOEMBRYONIC ANTIGEN FAMILY(iii)NUMBER OF SEQUENCES: 1(iv) CORRESPONDENCE ADDRESS:(A)     ADDRESSEE: SPRUNG HORN KRAMER &amp; WOODS(B)     STREET: 1140 AVENUE OF THE AMERICAS(C)     CITY: NEW YORK(D)     STATE: NEW YORK(E)     COUNTRY: U.S.A.(F)     ZIP: 10036(v)  COMPUTER READABLE FORM:(A)     MEDIUM TYPE: Floppy disk(B)     COMPUTER: IBM PC compatible(C)     OPERATING SYSTEM: PC-DOS/MS-DOS(D)     SOFTWARE: PatentIn Release #1.0, Version #1.25(vi) CURRENT APPLICATION DATA:(A)     APPLICATION NUMBER: US 07/760,031(B)     FILING DATE: 13-NOV-1991(C)     CLASSIFICATION: UNASSIGNED(viii)ATTORNEY/AGENT INFORMATION:(A)     NAME: VASTA JR, VINCENT J(B)     REGISTRATION NUMBER: 26,655(C)     REFERENCE/DOCKET NUMBER: MDI 242.5-VJV(ix) TELECOMMUNICATION INFORMATION:(A)     TELEPHONE: (212) 391-0520(B)     TELEFAX: (212) 382-0949(C)     TELEX: 423092 NYP UI(2)  INFORMATION FOR SEQ ID NO:11:(i)  SEQUENCE CHARACTERISTICS:(A)     LENGTH: 526 amino acids(B)     TYPE: amino acid(D)     TOPOLOGY: linear(ii) MOLECULE TYPE: peptide(iii)HYPOTHETICAL: YES(iv) ORIGINAL SOURCE:(A)     ORGANISM: HOMO SAPIENS(vii)IMMEDIATE SOURCE:(B)     CLONE: TRANSLATED POLYPEPTIDE FROM CEA-(c) cDNA(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:Met   Gly His    Leu       Ser          Ala             Pro                Leu                   His                      Arg                         Val                            Arg                               Val                                  Pro                                     Trp                                        Gln1           5              10             15Gly   Leu Leu    Leu       Thr          Ala             Ser                Leu                   Leu                      Thr                         Phe                            Trp                               Asn                                  Pro                                     Pro                                        Thr    20             25             30Thr   Ala Gln    Leu       Thr          Thr             Glu                Ser                   Met                      Pro                         Phe                            Asn                               Val                                  Ala                                     Glu                                        Gly 35             40             45Lys   Glu Val    Leu       Leu          Leu             Val                His                   Asn                      Leu                         Pro                            Gln                               Gln                                  Leu                                     Phe                                        Gly   50             55             50Tyr   Ser Trp    Tyr       Lys          Gly             Glu                Arg                   Val                      Asp                         Gly                            Asn                               Arg                                  Gln                                     Ile                                        Val65             70             75             80Gly   Tyr Ala    Ile       Gly          Thr             Gln                Gln                   Ala                      Thr                         Pro                            Gly                               Pro                                  Ala                                     Asn                                        Ser       85             90             95Gly   Arg Glu    Thr       Ile          Tyr             Pro                Asn                   Ala                      Ser                         Leu                            Leu                               Ile                                  Gln                                     Asn                                        Val    100            105            110Thr   Gln Asn    Asp       Thr          Gly             Phe                Tyr                   Thr                      Leu                         Gln                            Val                               Ile                                  Lys                                     Ser                                        Asp 115            120            125Leu   Val Asn    Glu       Glu          Ala             Thr                Gly                   Gln                      Phe                         His                            Val                               Tyr                                  Pro                                     Glu                                        Leu   130            135            140Pro   Lys Pro    Ser       Ile          Ser             Ser                Asn                   Asn                      Ser                         Asn                            Pro                               Val                                  Glu                                     Asp                                        Lys145            150            155            160Asp   Ala Val    Ala       Phe          Thr             Cys                Glu                   Pro                      Glu                         Thr                            Gln                               Asp                                  Thr                                     Thr                                        Tyr       165            170            175Leu   Trp Trp    Ile       Asn          Asn             Gln                Ser                   Leu                      Pro                         Val                            Ser                               Pro                                  Arg                                     Leu                                        Gln    180            185            190Leu   Ser Asn    Gly       Asn          Arg             Thr                Leu                   Thr                      Leu                         Leu                            Ser                               Val                                  Thr                                     Arg                                        Asn 195            200            205Asp   Thr Gly    Pro       Tyr          Glu             Cys                Clu                   Ile                      Gln                         Asn                            Pro                               Val                                  Ser                                     Ala                                        Asn   210            215            220Arg   Ser Asp    Pro       Val          Thr             Leu                Asn                   Val                      Thr                         Tyr                            Gly                               Pro                                  Asp                                     Thr                                        Pro225            230            235            240Thr   Ile Ser    Pro       Ser          Asp             Thr                Tyr                   Tyr                      Arg                         Pro                            Gly                               Ala                                  Asn                                     Leu                                        Ser       245            250            255Leu   Ser Cys    Tyr       Ala          Ala             Ser                Asn                   Pro                      Pro                         Ala                            Gln                               Tyr                                  Ser                                     Trp                                        Leu    260            265            270Ile   Asn Gly    Thr       Phe          Gln             Gln                Ser                   Thr                      Gln                         Glu                            Leu                               Phe                                  Ile                                     Pro                                        Asn 275            280            285Ile   Thr Val    Asn       Asn          Ser             Gly                Ser                   Tyr                      Thr                         Cys                            His                               Ala                                  Asn                                     Asn                                        Ser   290            295            300Val   Thr Gly    Cys       Asn          Arg             Thr                Thr                   Val                      Lys                         Thr                            Ile                               Ile                                  Val                                     Thr                                        Glu305            310            315            320Leu   Ser Pro    Val       Val          Ala             Lys                Pro                   Gln                      Ile                         Lys                            Ala                               Ser                                  Lys                                     Thr                                        Thr       325            330            335Val   Thr Gly    Asp       Lys          Asp             Ser                Val                   Asn                      Leu                         Thr                            Cys                               Ser                                  Thr                                     Asn                                        Asp    340            345            350Thr   Gly Ile    Ser       Ile          Arg             Trp                Phe                   Phe                      Lys                         Asn                            Gln                               Ser                                  Leu                                     Pro                                        Ser 355            360            365Ser   Glu Arg    Met       Lys          Leu             Ser                Gln                   Gly                      Asn                         Thr                            Thr                               Leu                                  Ser                                     Ile                                        Asn   370            375            380Pro   Val Lys    Arg       Glu          Asp             Ala                Gly                   Thr                      Tyr                         Trp                            Cys                               Glu                                  Val                                     Phe                                        Asn385            390            395            400Pro   Ile Ser    Lys       Asn          Gln             Ser                Asp                   Pro                      Ile                         Met                            Leu                               Asn                                  Val                                     Asn                                        Tyr       405            410            415Asn   Ala Leu    Pro       Gln          Glu             Asn                Gly                   Leu                      Ser                         Pro                            Gly                               Ala                                  Ile                                     Ala                                        Gly    420            425            430Ile   Val Ile    Gly       Val          Val             Ala                Leu                   Val                      Ala                         Leu                            Ile                               Ala                                  Val                                     Ala                                        Leu 435            440            445Ala   Cys Phe    Leu       His          Phe             Gly                Lys                   Thr                      Gly                         Arg                            Ala                               Ser                                  Asp                                     Gln                                        Arg   450            455            460Asp   Leu Thr    Glu       His          Lys             Pro                Ser                   Val                      Ser                         Asn                            His                               Thr                                  Gln                                     Asp                                        His465            470            475            480Ser   Asn Asp    Pro       Pro          Asn             Lys                Met                   Asn                      Glu                         Val                            Thr                               Tyr                                  Ser                                     Thr                                        Leu       485            490            495Asn   Phe Glu    Ala       Gln          Gln             Pro                Thr                   Gln                      Pro                         Thr                            Ser                               Ala                                  Ser                                     Pro                                        Ser    500            505            510Leu   Thr Ala    Thr       Glu          Ile             Ile                Tyr                   Ser                      Glu                         Val                            Lys                               Lys                                  Gln 515            520            525__________________________________________________________________________ 
    
     
         __________________________________________________________________________SEQUENCE LISTING__________________________________________________________________________(1)  GENERAL INFORMATION:(i)  APPLICANT:         BARNETT, THOMAS R         ELTING, JAMES J         KAMARCK, MICHAEL E         KRETSCHMER, A W(ii) TITLE OF INVENTION: CDNAS CODING FOR MEMBERS OF THECARCINOEMBRYONIC ANTIGEN FAMILY(iii)NUMBER OF SEQUENCES: 1(iv) CORRESPONDENCE ADDRESS:(A)     ADDRESSEE: SPRUNG HORN KRAMER &amp; WOODS(B)     STREET: 1140 AVENUE OF THE AMERICAS(C)     CITY: NEW YORK(D)     STATE: NEW YORK(E)     COUNTRY: U.S.A.(F)     ZIP: 10036(v)  COMPUTER READABLE FORM:(A)     MEDIUM TYPE: Floppy disk(B)     COMPUTER: IBM PC compatible(C)     OPERATING SYSTEM: PC-DOS/MS-DOS(D)     SOFTWARE: PatentIn Release #1.0, Version #1.25(vi) CURRENT APPLICATION DATA:(A)     APPLICATION NUMBER: US 07/760,031(B)     FILING DATE: 13-NOV-1991(C)     CLASSIFICATION: UNASSIGNED(viii)ATTORNEY/AGENT INFORMATION:(A)     NAME: VASTA JR, VINCENT J(B)     REGISTRATION NUMBER: 26,655(C)     REFERENCE/DOCKET NUMBER: MDI 242.5-VJV(ix) TELECOMMUNICATION INFORMATION:(A)     TELEPHONE: (212) 391-0520(B)     TELEFAX: (212) 382-0949(C)     TELEX: 423092 NYP UI(2)  INFORMATION FOR SEQ ID NO:12:(i)  SEQUENCE CHARACTERISTICS:(A)     LENGTH: 344 amino acids(B)     TYPE: amino acid(D)     TOPOLOGY: linear(ii) MOLECULE TYPE: peptide(iii)HYPOTHETICAL: YES(vi) ORIGINAL SOURCE:(A)     ORGANISM: HOMO SAPIENS(vii)IMMEDIATE SOURCE:(B)     CLONE: TRANSLATED POLYPEPTIDE FROM CEA-(d) cDNA(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:Met   Gly Pro    Pro       Ser          Ala             Pro                Pro                   Cys                      Arg                         Leu                            His                               Val                                  Pro                                     Trp                                        Lys1           5              10             15Glu   Val Leu    Leu       Thr          Ala             Ser                Leu                   Leu                      Thr                         Phe                            Trp                               Asn                                  Pro                                     Pro                                        Thr    20             25             30Thr   Ala Lys    Leu       Thr          Ile             Glu                Ser                   Thr                      Pro                         Phe                            Asn                               Val                                  Ala                                     Glu                                        Gly 35             40             45Lys   Glu Val    Leu       Leu          Leu             Ala                His                   Asn                      Leu                         Pro                            Gln                               Asn                                  Arg                                     Ile                                        Gly   50             55             60Tyr   Ser Trp    Tyr       Lys          Gly             Glu                Arg                   Val                      Asp                         Gly                            Asn                               Ser                                  Leu                                     Ile                                        Val65             70             75             80Gly   Tyr Val    Ile       Gly          Thr             Gln                Gln                   Ala                      Thr                         Pro                            Gly                               Pro                                  Ala                                     Tyr                                        Ser       85             90             95Gly   Arg Glu    Thr       Ile          Tyr             Pro                Asn                   Ala                      Ser                         Leu                            Leu                               Ile                                  Gln                                     Asn                                        Val    100            105            110Thr   Gln Asn    Asp       Thr          Gly             Phe                Tyr                   Thr                      Leu                         Gln                            Val                               Ile                                  Lys                                     Ser                                        Asp 115            120            125Leu   Val Asn    Glu       Glu          Ala             Thr                Gly                   Gln                      Phe                         His                            Val                               Tyr                                  Pro                                     Glu                                        Leu   130            135            140Pro   Lys Pro    Ser       Ile          Ser             Ser                Asn                   Asn                      Ser                         Asn                            Pro                               Val                                  Glu                                     Asp                                        Lys145            150            155            160Asp   Ala Val    Ala       Phe          Thr             Cys                Glu                   Pro                      Glu                         Val                            Gln                               Asn                                  Thr                                     Thr                                        Tyr       165            170            175Leu   Trp Trp    Val       Asn          Gly             Gln                Ser                   Leu                      Pro                         Val                            Ser                               Pro                                  Arg                                     Leu                                        Gln    180            185            190Leu   Ser Asn    Gly       Asn          Arg             Thr                Leu                   Thr                      Leu                         Leu                            Ser                               Val                                  Lys                                     Arg                                        Asn 195            200            205Asp   Ala Gly    Ser       Tyr          Glu             Cys                Glu                   Ile                      Gln                         Asn                            Pro                               Ala                                  Ser                                     Ala                                        Asn   210            215            220Arg   Ser Asp    Pro       Val          Thr             Leu                Asn                   Val                      Leu                         Tyr                            Gly                               Pro                                  Asp                                     Gly                                        Pro225            230            235            240Thr   Ile Ser    Pro       Ser          Lys             Ala                Asn                   Tyr                      Arg                         Pro                            Gly                               Glu                                  Asn                                     Leu                                        Asn       245            250            255Leu   Ser Cys    His       Ala          Ala             Ser                Asn                   Pro                      Pro                         Ala                            Gln                               Tyr                                  Ser                                     Trp                                        Phe    260            265            270Ile   Asn Gly    Thr       Phe          Gln             Gln                Ser                   Thr                      Gln                         Glu                            Leu                               Phe                                  Ile                                     Pro                                        Asn 275            280            285Ile   Thr Val    Asn       Asn          Ser             Gly                Ser                   Tyr                      Met                         Cys                            Gln                               Ala                                  His                                     Asn                                        Ser   290            295            300Ala   Thr Gly    Leu       Asn          Arg             Thr                Thr                   Val                      Thr                         Met                            Ile                               Thr                                  Val                                     Ser                                        Gly305            310            315            320Ser   Ala Pro    Val       Leu          Ser             Ala                Val                   Ala                      Thr                         Val                            Gly                               Ile                                  Thr                                     Ile                                        Gly       325            330            335Val   Leu Ala    Arg       Val          Ala             Leu                Ile    340__________________________________________________________________________ 
    
     
         __________________________________________________________________________SEQUENCE LISTING__________________________________________________________________________(1)  GENERAL INFORMATION:(i)  APPLICANT:         BARNETT, THOMAS R         ELTING, JAMES J         KAMARCK, MICHAEL E         KRETSCHMER, A W(ii) TITLE OF INVENTION: CDNAS CODING FOR MEMBERS OF THECARCINOEMBRYONIC ANTIGEN FAMILY(iii)NUMBER OF SEQUENCES: 1(iv) CORRESPONDENCE ADDRESS:(A)     ADDRESSEE: SPRUNG HORN KRAMER &amp; WOODS(B)     STREET: 1140 AVENUE OF THE AMERICAS(C)     CITY: NEW YORK(D)     STATE: NEW YORK(E)     COUNTRY: U.S.A.(F)     ZIP: 10036(v)  COMPUTER READABLE FORM:(A)     MEDIUM TYPE: Floppy disk(B)     COMPUTER: IBM PC compatible(C)     OPERATING SYSTEM: PC-DOS/MS-DOS(D)     SOFTWARE: PatentIn Release #1.0, Version #1.25(vi) CURRENT APPLICATION DATA:(A)     APPLICATION NUMBER: US 07/760,031(B)     FILING DATE: 13-NOV-1991(C)     CLASSIFICATION: UNASSIGNED(viii)ATTORNEY/AGENT INFORMATION:(A)     NAME: VASTA JR, VINCENT J(B)     REGISTRATION NUMBER: 26,655(C)     REFERENCE/DOCKET NUMBER: MDI 242.5-VJV(ix) TELECOMMUNICATION INFORMATION:(A)     TELEPHONE: (212) 391-0520(B)     TELEFAX: (212) 382-0949(C)     TELEX: 423092 NYP UI(2)  INFORMATION FOR SEQ ID NO:13:(i)  SEQUENCE CHARACTERISTICS:(A)     LENGTH: 430 amino acids(B)     TYPE: amino acid(D)     TOPOLOGY: linear(ii) MOLECULE TYPE: peptide(iii)HYPOTHETICAL: YES(vi) ORIGINAL SOURCE:(A)     ORGANISM: HOMO SAPIENS(vii)IMMEDIATE SOURCE:(B)     CLONE: TRANSLATED POLYPEPTIDE FROM CEA-(e) cDNA(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:Met   Gly His    Leu       Ser          Ala             Pro                Leu                   His                      Arg                         Val                            Arg                               Val                                  Pro                                     Trp                                        Gln1           5              10             15Gly   Leu Leu    Leu       Thr          Ala             Ser                Leu                   Leu                      Thr                         Phe                            Trp                               Asn                                  Pro                                     Pro                                        Thr    20             25             30Thr   Ala Gln    Leu       Thr          Thr             Glu                Ser                   Met                      Pro                         Phe                            Asn                               Val                                  Ala                                     Glu                                        Gly 35             40             45Lys   Glu Val    Leu       Leu          Leu             Val                His                   Asn                      Leu                         Pro                            Gln                               Gln                                  Leu                                     Phe                                        Gly   50             55             60Tyr   Ser Trp    Tyr       Lys          Gly             Glu                Arg                   Val                      Asp                         Gly                            Asn                               Arg                                  Gln                                     Ile                                        Val65             70             75             80Gly   Tyr Ala    Ile       Gly          Thr             Gln                Gln                   Ala                      Thr                         Pro                            Gly                               Pro                                  Ala                                     Asn                                        Ser       85             90             95Gly   Arg Glu    Thr       Ile          Tyr             Pro                Asn                   Ala                      Ser                         Leu                            Leu                               Ile                                  Gln                                     Asn                                        Val    100            105            110Thr   Gln Asn    Asp       Thr          Gly             Phe                Tyr                   Thr                      Leu                         Gln                            Val                               Ile                                  Lys                                     Ser                                        Asp 115            120            125Leu   Val Asn    Glu       Glu          Ala             Thr                Gly                   Gln                      Phe                         His                            Val                               Tyr                                  Pro                                     Glu                                        Leu   130            135            140Pro   Lys Pro    Ser       Ile          Ser             Ser                Asn                   Asn                      Ser                         Asn                            Pro                               Val                                  Gly                                     Asp                                        Lys145            150            155            160Asp   Ala Val    Ala       Phe          Thr             Cys                Glu                   Pro                      Glu                         Thr                            Gln                               Asp                                  Thr                                     Thr                                        Tyr       165            170            175Leu   Trp Trp    Ile       Asn          Asn             Gln                Ser                   Leu                      Pro                         Val                            Ser                               Pro                                  Arg                                     Leu                                        Gln    180            185            190Leu   Ser Asn    Gly       Asn          Arg             Thr                Leu                   Thr                      Leu                         Leu                            Ser                               Val                                  Thr                                     Arg                                        Asn 195            200            205Asp   Thr Gly    Pro       Tyr          Glu             Cys                Glu                   Ile                      Gln                         Asn                            Pro                               Val                                  Ser                                     Ala                                        Asn   210            215            220Arg   Ser Asp    Pro       Val          Thr             Leu                Asn                   Val                      Thr                         Tyr                            Gly                               Pro                                  Asp                                     Thr                                        Pro225            230            235            240Thr   Ile Ser    Pro       Ser          Asp             Thr                Tyr                   Tyr                      Arg                         Pro                            Gly                               Ala                                  Asn                                     Leu                                        Ser       245            250            255Leu   Ser Cys    Tyr       Ala          Ala             Ser                Asn                   Pro                      Pro                         Ala                            Gln                               Tyr                                  Ser                                     Trp                                        Leu    260            265            270Ile   Asn Gly    Thr       Phe          Gln             Gln                Ser                   Thr                      Gln                         Glu                            Leu                               Phe                                  Ile                                     Pro                                        Asn 275            280            285Ile   Thr Val    Asn       Asn          Ser             Gly                Ser                   Tyr                      Thr                         Cys                            His                               Ala                                  Asn                                     Asn                                        Ser   290            295            300Val   Thr Gly    Cys       Asn          Arg             Thr                Thr                   Val                      Lys                         Thr                            Ile                               Ile                                  Val                                     Thr                                        Asp305            310            315            320Asn   Ala Leu    Pro       Gln          Glu             Asn                Gly                   Leu                      Ser                         Pro                            Gly                               Ala                                  Ile                                     Ala                                        Gly       325            330            335Ile   Val Ile    Gly       Val          Val             Ala                Leu                   Val                      Ala                         Leu                            Ile                               Ala                                  Val                                     Ala                                        Leu    340            345            350Ala   Cys Phe    Leu       His          Phe             Gly                Lys                   Thr                      Gly                         Arg                            Ala                               Ser                                  Asp                                     Gln                                        Arg 355            360            365Asp   Leu Thr    Glu       His          Lys             Pro                Ser                   Val                      Ser                         Asn                            His                               Thr                                  Gln                                     Asp                                        His   370            375            380Ser   Asn Asp    Pro       Pro          Asn             Lys                Met                   Asn                      Glu                         Val                            Thr                               Tyr                                  Ser                                     Thr                                        Leu385            390            395            400Asn   Phe Glu    Ala       Gln          Gln             Pro                Thr                   Gln                      Pro                         Thr                            Ser                               Ala                                  Ser                                     Pro                                        Ser       405            410            415Leu   Thr Ala    Thr       Glu          Ile             Ile                Tyr                   Ser                      Glu                         Val                            Lys                               Lys                                  Gln    420            425            430__________________________________________________________________________ 
    
     
         __________________________________________________________________________SEQUENCE LISTING__________________________________________________________________________(1)  GENERAL INFORMATION:(i)  APPLICANT:         BARNETT, THOMAS R         ELTING, JAMES J         KAMARCK, MICHAEL E         KRETSCHMER, A W(ii) TITLE OF INVENTION: CDNAS CODING FOR MEMBERS OF THECARCINOEMBRYONIC ANTIGEN FAMILY(iii)NUMBER OF SEQUENCES: 1(iv) CORRESPONDENCE ADDRESS:(A)     ADDRESSEE: SPRUNG HORN KRAMER &amp; WOODS(B)     STREET: 1140 AVENUE OF THE AMERICAS(C)     CITY: NEW YORK(D)     STATE: NEW YORK(E)     COUNTRY: U.S.A.(F)     ZIP: 10036(v)  COMPUTER READABLE FORM:(A)     MEDIUM TYPE: Floppy disk(B)     COMPUTER: IBM PC compatible(C)     OPERATING SYSTEM: PC-DOS/MS-DOS(D)     SOFTWARE: PatentIn Release #1.0, Version #1.25(vi) CURRENT APPLICATION DATA:(A)     APPLICATION NUMBER: US 07/760,031(B)     FILING DATE: 13-NOV-1991(C)     CLASSIFICATION: UNASSIGNED(viii)ATTORNEY/AGENT INFORMATION:(A)     NAME: VASTA JR, VINCENT J(B)     REGISTRATION NUMBER: 26,655(C)     REFERENCE/DOCKET NUMBER: MDI 242.5-VJV(ix) TELECOMMUNICATION INFORMATION:(A)     TELEPHONE: (212) 391-0520(B)     TELEFAX: (212) 382-0949(C)     TELEX: 423092 NYP UI(2)  INFORMATION FOR SEQ ID NO:14:(i)  SEQUENCE CHARACTERISTICS:(A)     LENGTH: 464 amino acids(B)     TYPE: amino acid(D)     TOPOLOGY: linear(ii) MOLECULE TYPE: peptide(iii)HYPOTHETICAL: YES(vi) ORIGINAL SOURCE:(A)     ORGANISM: HOMO SAPIENS(vii)IMMEDIATE SOURCE:(B)     CLONE: TRANSLATED POLYPEPTIDE FROM CEA-(f) cDNA(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:Met   Gly His    Leu       Ser          Ala             Pro                Leu                   His                      Arg                         Val                            Arg                               Val                                  Pro                                     Trp                                        Gln1           5              10             15Gly   Leu Leu    Leu       Thr          Ala             Ser                Leu                   Leu                      Thr                         Phe                            Trp                               Asn                                  Pro                                     Pro                                        Thr    20             25             30Thr   Ala Gln    Leu       Thr          Thr             Glu                Ser                   Met                      Pro                         Phe                            Asn                               Val                                  Ala                                     Glu                                        Gly 35             40             45Lys   Glu Val    Leu       Leu          Leu             Val                His                   Asn                      Leu                         Pro                            Gln                               Gln                                  Leu                                     Phe                                        Gly   50             55             60Tyr   Ser Trp    Tyr       Lys          Gly             Glu                Arg                   Val                      Asp                         Gly                            Asn                               Arg                                  Gln                                     Ile                                        Val65             70             75             80Gly   Tyr Ala    Ile       Gly          Thr             Gln                Gln                   Ala                      Thr                         Pro                            Gly                               Pro                                  Ala                                     Asn                                        Ser       85             90             95Gly   Arg Glu    Thr       Ile          Tyr             Pro                Asn                   Ala                      Ser                         Leu                            Leu                               Ile                                  Gln                                     Asn                                        Val    100            105            110Thr   Gln Asn    Asp       Thr          Gly             Phe                Tyr                   Thr                      Leu                         Gln                            Val                               Ile                                  Lys                                     Ser                                        Asp 115            120            125Leu   Val Asn    Glu       Glu          Ala             Thr                Gly                   Gln                      Phe                         His                            Val                               Tyr                                  Pro                                     Glu                                        Leu   130            135            140Pro   Lys Pro    Ser       Ile          Ser             Ser                Asn                   Asn                      Ser                         Asn                            Pro                               Val                                  Glu                                     Asp                                        Lys145            150            155            160Asp   Ala Val    Ala       Phe          Thr             Cys                Glu                   Pro                      Glu                         Thr                            Gln                               Asp                                  Thr                                     Thr                                        Tyr       165            170            175Leu   Trp Trp    Ile       Asn          Asn             Gln                Ser                   Leu                      Pro                         Val                            Ser                               Pro                                  Arg                                     Leu                                        Gln    180            185            190Leu   Ser Asn    Gly       Asn          Arg             Thr                Leu                   Thr                      Leu                         Leu                            Ser                               Val                                  Thr                                     Arg                                        Asn 195            200            205Asp   Thr Gly    Pro       Tyr          Glu             Cys                Glu                   Ile                      Gln                         Asn                            Pro                               Val                                  Ser                                     Ala                                        Asn   210            215            220Arg   Ser Asp    Pro       Val          Thr             Leu                Asn                   Val                      Thr                         Tyr                            Gly                               Pro                                  Asp                                     Thr                                        Pro225            230            235            240Thr   Ile Ser    Pro       Ser          Asp             Thr                Tyr                   Tyr                      Arg                         Pro                            Gly                               Ala                                  Asn                                     Leu                                        Ser       245            250            255Leu   Ser Cys    Tyr       Ala          Ala             Ser                Asn                   Pro                      Pro                         Ala                            Gln                               Tyr                                  Ser                                     Trp                                        Leu    260            265            270Ile   Asn Gly    Thr       Phe          Gln             Gln                Ser                   Thr                      Gln                         Glu                            Leu                               Phe                                  Ile                                     Pro                                        Asn 275            280            285Ile   Thr Val    Asn       Asn          Ser             Gly                Ser                   Tyr                      Thr                         Cys                            His                               Ala                                  Asn                                     Asn                                        Ser   290            295            300Val   Thr Gly    Cys       Asn          Arg             Thr                Thr                   Val                      Lys                         Thr                            Ile                               Ile                                  Val                                     Thr                                        Glu305            310            315            320Leu   Ser Pro    Val       Val          Ala             Lys                Pro                   Gln                      Ile                         Lys                            Ala                               Ser                                  Lys                                     Thr                                        Thr       325            330            335Val   Thr Gly    Asp       Lys          Asp             Ser                Val                   Asn                      Leu                         Thr                            Cys                               Ser                                  Thr                                     Asn                                        Asp    340            345            350Thr   Gly Ile    Ser       Ile          Arg             Trp                Phe                   Phe                      Lys                         Asn                            Gln                               Ser                                  Leu                                     Pro                                        Ser 355            360            365Ser   Glu Arg    Met       Lys          Leu             Ser                Gln                   Gly                      Asn                         Thr                            Thr                               Leu                                  Ser                                     Ile                                        Asn   370            375            380Pro   Val Lys    Arg       Glu          Asp             Ala                Gly                   Thr                      Tyr                         Trp                            Cys                               Glu                                  Val                                     Phe                                        Asn385            390            395            400Pro   Ile Ser    Lys       Asn          Gln             Ser                Asp                   Pro                      Ile                         Met                            Leu                               Asn                                  Val                                     Asn                                        Tyr       405            410            415Asn   Ala Leu    Pro       Gln          Glu             Asn                Gly                   Leu                      Ser                         Pro                            Gly                               Ala                                  Ile                                     Ala                                        Gly    420            425            430Ile   Val Ile    Gly       Val          Val             Ala                Leu                   Val                      Ala                         Leu                            Ile                               Ala                                  Val                                     Ala                                        Leu 435            440            445Ala   Cys Phe    Leu       His          Phe             Gly                Lys                   Thr                      Gly                         Ser                            Ser                               Gly                                  Pro                                     Leu                                        Gln   450            455            460__________________________________________________________________________ 
    
     
         __________________________________________________________________________SEQUENCE LISTING__________________________________________________________________________(1)  GENERAL INFORMATION:(i)  APPLICANT:         BARNETT, THOMAS R         ELTING, JAMES J         KAMARCK, MICHAEL E         KRETSCHMER, A W(ii) TITLE OF INVENTION: CDNAS CODING FOR MEMBERS OF THECARCINOEMBRYONIC ANTIGEN FAMILY(iii)NUMBER OF SEQUENCES: 1(iv) CORRESPONDENCE ADDRESS:(A)     ADDRESSEE: SPRUNG HORN KRAMER &amp; WOODS(B)     STREET: 1140 AVENUE OF THE AMERICAS(C)     CITY: NEW YORK(D)     STATE: NEW YORK(E)     COUNTRY: U.S.A.(F)     ZIP: 10036(v)  COMPUTER READABLE FORM:(A)     MEDIUM TYPE: Floppy disk(B)     COMPUTER: IBM PC compatible(C)     OPERATING SYSTEM: PC-DOS/MS-DOS(D)     SOFTWARE: PatentIn Release #1.0, Version #1.25(vi) CURRENT APPLICATION DATA:(A)     APPLICATION NUMBER: US 07/760,031(B)     FILING DATE: 13-NOV-1991(C)     CLASSIFICATION: UNASSIGNED(viii)ATTORNEY/AGENT INFORMATION:(A)     NAME: VASTA JR, VINCENT J(B)     REGISTRATION NUMBER: 26,655(C)     REFERENCE/DOCKET NUMBER: MDI 242.5-VJV(ix) TELECOMMUNICATION INFORMATION:(A)     TELEPHONE: (212) 391-0520(B)     TELEFAX: (212) 382-0949(C)     TELEX: 423092 NYP UI(2)  INFORMATION FOR SEQ ID NO:15:(i)  SEQUENCE CHARACTERISTICS:(A)     LENGTH: 368 amino acids(B)     TYPE: amino acid(D)     TOPOLOGY: linear(ii) MOLECULE TYPE: peptide(iii)HYPOTHETICAL: YES(vii)IMMEDIATE SOURCE:(B)     CLONE: TRANSLATED POLYPEPTIDE FROM CEA-(g) cDNA(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:Met   Gly His    Leu       Ser          Ala             Pro                Leu                   His                      Arg                         Val                            Arg                               Val                                  Pro                                     Trp                                        Gln1           5              10             15Gly   Leu Leu    Leu       Thr          Ala             Ser                Leu                   Leu                      Thr                         Phe                            Trp                               Asn                                  Pro                                     Pro                                        Thr    20             25             30Thr   Ala Gln    Leu       Thr          Thr             Glu                Ser                   Met                      Pro                         Phe                            Asn                               Val                                  Ala                                     Glu                                        Gly 35             40             45Lys   Glu Val    Leu       Leu          Leu             Val                His                   Asn                      Leu                         Pro                            Gln                               Gln                                  Leu                                     Phe                                        Gly   50             55             60Tyr   Ser Trp    Tyr       Lys          Gly             Glu                Arg                   Val                      Asp                         Gly                            Asn                               Arg                                  Gln                                     Ile                                        Val65             70             75             80Gly   Tyr Ala    Ile       Gly          Thr             Gln                Gln                   Ala                      Thr                         Pro                            Gly                               Pro                                  Ala                                     Asn                                        Ser       85             90             95Gly   Arg Glu    Thr       Ile          Tyr             Pro                Asn                   Ala                      Ser                         Leu                            Leu                               Ile                                  Gln                                     Asn                                        Val    100            105            110Thr   Gln Asn    Asp       Thr          Gly             Phe                Tyr                   Thr                      Leu                         Gln                            Val                               Ile                                  Lys                                     Ser                                        Asp 115            120            125Leu   Val Asn    Glu       Glu          Ala             Thr                Gly                   Gln                      Phe                         His                            Val                               Tyr                                  Pro                                     Glu                                        Leu   130            135            140Pro   Lys Pro    Ser       Ile          Ser             Ser                Asn                   Asn                      Ser                         Asn                            Pro                               Val                                  Glu                                     Asp                                        Lys145            150            155            160Asp   Ala Val    Ala       Phe          Thr             Cys                Glu                   Pro                      Glu                         Thr                            Gln                               Asp                                  Thr                                     Thr                                        Thr       165            170            175Leu   Trp Trp    Ile       Asn          Asn             Gln                Ser                   Leu                      Pro                         Val                            Ser                               Pro                                  Arg                                     Leu                                        Gln    180            185            190Leu   Ser Asn    Gly       Asn          Arg             Thr                Leu                   Thr                      Leu                         Leu                            Ser                               Val                                  Thr                                     Arg                                        Asn 195            200            205Asp   Thr Gly    Pro       Tyr          Glu             Cys                Glu                   Ile                      Gln                         Asn                            Pro                               Val                                  Ser                                     Ala                                        Asn   210            215            220Arg   Ser Asp    Pro       Val          Thr             Leu                Asn                   Val                      Thr                         Tyr                            Gly                               Pro                                  Asp                                     Thr                                        Pro225            230            235            240Thr   Ile Ser    Pro       Ser          Asp             Thr                Tyr                   Tyr                      Arg                         Pro                            Gly                               Ala                                  Asn                                     Leu                                        Ser       245            250            255Leu   Ser Cys    Tyr       Ala          Ala             Ser                Asn                   Pro                      Pro                         Ala                            Gln                               Tyr                                  Ser                                     Trp                                        Leu    260            265            270Ile   Asn Gly    Thr       Phe          Gln             Gln                Ser                   Thr                      Gln                         Glu                            Leu                               Phe                                  Ile                                     Pro                                        Asn 275            280            285Ile   Thr Val    Asn       Asn          Ser             Gly                Ser                   Tyr                      Thr                         Cys                            His                               Ala                                  Asn                                     Asn                                        Ser   290            295            300Val   Thr Gly    Cys       Asn          Arg             Thr                Thr                   Val                      Lys                         Thr                            Ile                               Ile                                  Val                                     Thr                                        Asp305            310            315            320Asn   Ala Leu    Pro       Gln          Glu             Asn                Gly                   Leu                      Ser                         Pro                            Gly                               Ala                                  Ile                                     Ala                                        Gly       325            330            335Ile   Val Ile    Gly       Val          Val             Ala                Leu                   Val                      Ala                         Leu                            Ile                               Ala                                  Val                                     Ala                                        Leu    340            345            350Ala   Cys Phe    Leu       His          Phe             Gly                Lys                   Thr                      Gly                         Ser                            Ser                               Gly                                  Pro                                     Leu                                        Gln 355            360            365__________________________________________________________________________ 
    
     
         __________________________________________________________________________SEQUENCE LISTING__________________________________________________________________________(1)  GENERAL INFORMATION:(i)  APPLICANT:         BARNETT, THOMAS R         ELTING, JAMES J         KAMARCK, MICHAEL E         KRETSCHMER, A W(ii) TITLE OF INVENTION: CDNAS CODING FOR MEMBERS OF THECARCINOEMBRYONIC ANTIGEN FAMILY(iii)NUMBER OF SEQUENCES: 1(iv) CORRESPONDENCE ADDRESS:(A)     ADDRESSEE: SPRUNG HORN KRAMER &amp; WOODS(B)     STREET: 1140 AVENUE OF THE AMERICAS(C)     CITY: NEW YORK(D)     STATE: NEW YORK(E)     COUNTRY: U.S.A.(F)     ZIP: 10036(v)  COMPUTER READABLE FORM:(A)     MEDIUM TYPE: Floppy disk(B)     COMPUTER: IBM PC compatible(C)     OPERATING SYSTEM: PC-DOS/MS-DOS(D)     SOFTWARE: PatentIn Release #1.0, Version #1.25(vi) CURRENT APPLICATION DATA:(A)     APPLICATION NUMBER: US 07/760,031(B)     FILING DATE: 13-NOV-1991(C)     CLASSIFICATION: UNASSIGNED(viii)ATTORNEY/AGENT INFORMATION:(A)     NAME: VASTA JR, VINCENT J(B)     REGISTRATION NUMBER: 26,655(C)     REFERENCE/DOCKET NUMBER: MDI 242.5-VJV(ix) TELECOMMUNICATION INFORMATION:(A)     TELEPHONE: (212) 391-0520(B)     TELEFAX: (212) 382-0949(C)     TELEX: 423092 NYP UI(2)  INFORMATION FOR SEQ ID NO:16:(i)  SEQUENCE CHARACTERISTICS:(A)     LENGTH: 419 amino acids(B)     TYPE: amino acid(D)     TOPOLOGY: linear(ii) MOLECULE TYPE: peptide(iii)HYPOTHETICAL: YES(iv) ANTI-SENSE: NO(vi) ORIGINAL SOURCE:(A)     ORGANISM: HOMO SAPIENS(vii)IMMEDIATE SOURCE:(B)     CLONE: TRANSLATED POLYPEPTIDE FROM KGCEA1 cDNA(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:Met   Gly Pro    Leu       Ser          Ala             Pro                Pro                   Cys                      Thr                         His                            Leu                               Ile                                  Thr                                     Trp                                        Lys1           5              10             15Gly   Val Leu    Leu       Thr          Ala             Ser                Leu                   Leu                      Asn                         Phe                            Trp                               Asn                                  Pro                                     Pro                                        Thr    20             25             30Thr   Ala Gln    Val       Thr          Ile             Glu                Ala                   Gln                      Pro                         Pro                            Lys                               Val                                  Ser                                     Glu                                        Gly 35             40             45Lys   Asp Val    Leu       Leu          Leu             Val                His                   Asn                      Leu                         Pro                            Gln                               Asn                                  Leu                                     Ala                                        Gly   50             55             60Tyr   Ile Trp    Tyr       Lys          Gly             Gln                Met                   Thr                      Tyr                         Val                            Tyr                               His                                  Tyr                                     Ile                                        Thr65             70             75             80Ser   Tyr Val    Val       Asp          Gly             Gln                Arg                   Ile                      Ile                         Tyr                            Gly                               Pro                                  Ala                                     Tyr                                        Ser       85             90             95Gly   Arg Glu    Arg       Val          Tyr             Ser                Asn                   Ala                      Ser                         Leu                            Leu                               Ile                                  Gln                                     Asn                                        Val    100            105            110Thr   Gln Glu    Asp       Ala          Gly             Ser                Tyr                   Thr                      Leu                         His                            Ile                               Ile                                  Lys                                     Arg                                        Arg 115            120            125Asp   Gly Thr    Gly       Gly          Val             Thr                Gly                   His                      Phe                         Thr                            Phe                               Thr                                  Leu                                     His                                        Leu   130            135            140Glu   Thr Pro    Lys       Pro          Ser             Ile                Ser                   Ser                      Ser                         Asn                            Leu                               Asn                                  Pro                                     Arg                                        Glu145            150            155            160Ala   Met Glu    Ala       Val          Ile             Leu                Thr                   Cys                      Asp                         Pro                            Ala                               Thr                                  Pro                                     Ala                                        Ala       165            170            175Ser   Tyr Gln    Trp       Trp          Met             Asn                Gly                   Gln                      Ser                         Leu                            Pro                               Met                                  Thr                                     His                                        Arg    180            185            190Leu   Gln Leu    Ser       Lys          Thr             Asn                Arg                   Thr                      Leu                         Phe                            Ile                               Phe                                  Gly                                     Val                                        Thr 195            200            205Lys   Tyr Ile    Ala       Gly          Pro             Tyr                Glu                   Cys                      Glu                         Ile                            Arg                               Asn                                  Pro                                     Val                                        Ser   210            215            220Ala   Ser Arg    Ser       Asp          Pro             Val                Thr                   Leu                      Asn                         Leu                            Leu                               Pro                                  Lys                                     Leu                                        Ser225            230            235            240Lys   Pro Tyr    Ile       Thr          Ile             Asn                Asn                   Leu                      Asn                         Pro                            Arg                               Glu                                  Asn                                     Lys                                        Asp       245            250            255Val   Leu Thr    Phe       Thr          Cys             Glu                Pro                   Lys                      Ser                         Glu                            Asn                               Tyr                                  Thr                                     Tyr                                        Ile    260            265            270Trp   Trp Leu    Asn       Gly          Gln             Ser                Leu                   Pro                      Val                         Ser                            Pro                               Arg                                  Val                                     Lys                                        Arg 275            280            285Pro   Ile Glu    Asn       Arg          Ile             Leu                Ile                   Leu                      Pro                         Asn                            Val                               Thr                                  Arg                                     Asn                                        Glu   290            295            300Thr   Gly Pro    Tyr       Gln          Cys             Glu                Ile                   Arg                      Asp                         Arg                            Tyr                               Gly                                  Gly                                     Ile                                        Arg305            310            315            320Ser   Asp Pro    Val       Thr          Leu             Asn                Val                   Leu                      Tyr                         Gly                            Pro                               Asp                                  Leu                                     Pro                                        Ser       325            330            335Ile   Tyr Pro    Ser       Phe          Thr             Tyr                Tyr                   Arg                      Ser                         Gly                            Glu                               Asn                                  Leu                                     Tyr                                        Phe    340            345            350Ser   Cys Phe    Gly       Glu          Ser             Asn                Pro                   Arg                      Ala                         Gln                            Tyr                               Ser                                  Trp                                     Thr                                        Ile 355            360            365Asn   Gly Lys    Phe       Gln          Leu             Ser                Gly                   Gln                      Lys                         Leu                            Ser                               Ile                                  Pro                                     Gln                                        Ile   370            375            380Thr   Thr Lys    His       Ser          Gly             Leu                Tyr                   Ala                      Cys                         Ser                            Val                               Arg                                  Asn                                     Ser                                        Ala385            390            395            400Thr   Gly Lys    Glu       Ser          Ser             Lys                Ser                   Ile                      Thr                         Val                            Lys                               Val                                  Ser                                     Asp                                        Trp       405            410            415Ile   Leu Pro__________________________________________________________________________ 
    
     
         __________________________________________________________________________SEQUENCE LISTING__________________________________________________________________________(1)  GENERAL INFORMATION:(i)  APPLICANT:         BARNETT, THOMAS R         ELTING, JAMES J         KAMARCK, MICHAEL E         KRETSCHMER, A W(ii) TITLE OF INVENTION: CDNAS CODING FOR MEMBERS OF THECARCINOEMBRYONIC ANTIGEN FAMILY(iii)NUMBER OF SEQUENCES: 1(iv) CORRESPONDENCE ADDRESS:(A)     ADDRESSEE: SPRUNG HORN KRAMER &amp; WOODS(B)     STREET: 1140 AVENUE OF THE AMERICAS(C)     CITY: NEW YORK(D)     STATE: NEW YORK(E)     COUNTRY: U.S.A.(F)     ZIP: 10036(v)  COMPUTER READABLE FORM:(A)     MEDIUM TYPE: Floppy disk(B)     COMPUTER: IBM PC compatible(C)     OPERATING SYSTEM: PC-DOS/MS-DOS(D)     SOFTWARE: PatentIn Release #1.0, Version #1.25(vi) CURRENT APPLICATION DATA:(A)     APPLICATION NUMBER: US 07/760,031(B)     FILING DATE: 13-NOV-1991(C)     CLASSIFICATION: UNASSIGNED(viii)ATTORNEY/AGENT INFORMATION:(A)     NAME: VASTA JR, VINCENT J(B)     REGISTRATION NUMBER: 26,655(C)     REFERENCE/DOCKET NUMBER: MDI 242.5-VJV(ix) TELECOMMUNICATION INFORMATION:(A)     TELEPHONE: (212) 391-0520(B)     TELEFAX: (212) 382-0949(C)     TELEX: 423092 NYP UI(2)  INFORMATION FOR SEQ ID NO:17:(i)  SEQUENCE CHARACTERISTICS:(A)     LENGTH: 424 amino acids(B)     TYPE: amino acid(D)     TOPOLOGY: linear(ii) MOLECULE TYPE: peptide(iii)HYPOTHETICAL: YES(vii)IMMEDIATE SOURCE:(B)     CLONE: TRANSLATED POLYPEPTIDE FROM KGCEA2 cDNA(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:Met   Gly Pro    Leu       Ser          Ala             Pro                Pro                   Cys                      Thr                         Gln                            His                               Ile                                  Thr                                     Trp                                        Lys1           5              10             15Gly   Leu Leu    Leu       Thr          Ala             Ser                Leu                   Leu                      Asn                         Phe                            Trp                               Asn                                  Leu                                     Pro                                        Thr    20             25             30Thr   Ala Gln    Val       Ile          Ile             Glu                Ala                   Gln                      Pro                         Pro                            Lys                               Val                                  Ser                                     Glu                                        Gly 35             40             45Lys   Asp Val    Leu       Leu          Leu             Val                His                   Asn                      Leu                         Pro                            Gln                               Asn                                  Leu                                     Thr                                        Gly   50             55             60Tyr   Ile Trp    Tyr       Lys          Gly             Gln                Met                   Thr                      Asp                         Leu                            Tyr                               His                                  Tyr                                     Ile                                        Thr65             70             75             80Ser   Tyr Val    Val       Asp          Gly             Gln                Ile                   Ile                      Tyr                         Gly                            Pro                               Ala                                  Tyr                                     Ser                                        Gly       85             90             95Arg   Glu Thr    Val       Tyr          Ser             Asn                Ala                   Ser                      Leu                         Leu                            Ile                               Gln                                  Asn                                     Val                                        Thr    100            105            110Gln   Glu Asp    Ala       Gly          Ser             Tyr                Thr                   Leu                      His                         Ile                            Ile                               Lys                                  Arg                                     Gly                                        Asp 115            120            125Gly   Thr Gly    Gly       Val          Thr             Gly                Tyr                   Phe                      Thr                         Val                            Thr                               Leu                                  Tyr                                     Ser                                        Glu   130            135            140Thr   Pro Lys    Arg       Ser          Ile             Ser                Ser                   Ser                      Asn                         Leu                            Asn                               Pro                                  Arg                                     Glu                                        Val145            150            155            160Met   Glu Ala    Val       Arg          Leu             Ile                Cys                   Asp                      Pro                         Glu                            Thr                               Pro                                  Asp                                     Ala                                        Ser       165            170            175Tyr   Leu Trp    Leu       Leu          Asn             Gly                Gln                   Asn                      Leu                         Pro                            Met                               Thr                                  His                                     Arg                                        Leu    180            185            190Gln   Leu Ser    Lys       Thr          Asn             Arg                Thr                   Leu                      Tyr                         Leu                            Phe                               Gly                                  Val                                     Thr                                        Lys 195            200            205Tyr   Ile Ala    Gly       Pro          Tyr             Glu                Cys                   Glu                      Ile                         Arg                            Arg                               Gly                                  Val                                     Ser                                        Ala   210            215            220Ser   Arg Ser    Asp       Pro          Val             Thr                Leu                   Asn                      Leu                         Leu                            Pro                               Lys                                  Leu                                     Pro                                        Met225            230            235            240Pro   Tyr Ile    Thr       Ile          Asn             Asn                Leu                   Asn                      Pro                         Arg                            Glu                               Lys                                  Lys                                     Asp                                        Val       245            250            255Leu   Ala Phe    Thr       Cys          Glu             Pro                Lys                   Ser                      Arg                         Asn                            Tyr                               Thr                                  Tyr                                     Ile                                        Trp    260            265            270Trp   Leu Asn    Gly       Gln          Ser             Leu                Pro                   Val                      Ser                         Pro                            Arg                               Val                                  Lys                                     Arg                                        Pro 275            280            285Ile   Glu Asn    Arg       Ile          Leu             Ile                Leu                   Pro                      Ser                         Val                            Thr                               Arg                                  Asn                                     Glu                                        Thr   290            295            300Gly   Pro Tyr    Gln       Cys          Glu             Ile                Arg                   Asp                      Arg                         Tyr                            Gly                               Gly                                  Ile                                     Arg                                        Ser305            310            315            320Asn   Pro Val    Thr       Leu          Asn             Val                Leu                   Tyr                      Gly                         Pro                            Asp                               Leu                                  Pro                                     Arg                                        Ile       325            330            335Tyr   Pro Tyr    Phe       Thr          Tyr             Tyr                Arg                   Ser                      Gly                         Glu                            Asn                               Leu                                  Asp                                     Leu                                        Ser    340            345            350Cys   Phe Ala    Asp       Ser          Asn             Pro                Pro                   Ala                      Glu                         Tyr                            Phe                               Trp                                  Thr                                     Ile                                        Asn 355            360            365Gly   Lys Phe    Gln       Leu          Ser             Gly                Gln                   Lys                      Leu                         Phe                            Ile                               Pro                                  Gln                                     Ile                                        Thr   370            375            380Thr   Asn His    Ser       Gly          Leu             Tyr                Ala                   Cys                      Ser                         Val                            Arg                               Asn                                  Ser                                     Ala                                        Thr385            390            395            400Gly   Lys Glu    Ile       Ser          Lys             Ser                Met                   Ile                      Val                         Lys                            Val                               Ser                                  Gly                                     Pro                                        Cys       405            410            415His   Gly Asn    Gln       Thr          Glu             Ser                His    420__________________________________________________________________________